[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2179
1. Moore JS, Cataldo PA, Osler T, Hyman NH: Transanal endoscopic microsurgery is more effective than traditional transanal excision for resection of rectal masses. Dis Colon Rectum; 2008 Jul;51(7):1026-30; discussion 1030-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenoma / surgery. Carcinoid Tumor / surgery. Carcinoma in Situ / surgery. Colonic Polyps / surgery. Colonoscopy / methods. Microsurgery / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Aged. Anal Canal. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Outcome


2. Samuel S, Twizere JC, Bernstein LR: YB-1 represses AP1-dependent gene transactivation and interacts with an AP-1 DNA sequence. Biochem J; 2005 Jun 15;388(Pt 3):921-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Involvement of the AP-1 (activator protein-1) transcription factor has been demonstrated previously in the regulation of cell proliferation and cell-cycle progression, in the control of cell migration, invasion and metastasis, and in signal transduction, stress responsiveness, DNA replication and DNA repair.
  • In the present study, we report that overexpression of a transfected gene encoding YB-1 in human HeLa cervical carcinoma cells significantly represses the transactivation of a minimal AP-1 reporter construct in response to the tumour promoter PMA.
  • To identify new nuclear proteins that bind specifically to the AP-1 DNA-binding site, we devised a DNA-affinity-chromatography-based assay termed NAPSTER (nucleotide-affinity preincubation specificity test of recognition) and discovered a 49 kDa protein from human cancer cells that binds in a sequence-specific manner to the AP-1 DNA sequence.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1999 Nov 25;253(1):180-5 [10579922.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 23;1489(2-3):263-80 [10673028.001]
  • [Cites] J Biol Chem. 2000 Aug 18;275(33):25766-73 [10825169.001]
  • [Cites] Nucleic Acids Res. 2001 Mar 1;29(5):1200-7 [11222770.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2438-52 [11402339.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):32362-72 [11431474.001]
  • [Cites] Anal Biochem. 2001 Dec 15;299(2):203-10 [11730344.001]
  • [Cites] Mol Cell Biol. 2002 Jan;22(2):587-98 [11756554.001]
  • [Cites] J Leukoc Biol. 2002 Jan;71(1):9-15 [11781376.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):181-93 [11902573.001]
  • [Cites] Lancet Oncol. 2000 Nov;1:181-8 [11905657.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):E131-6 [11988758.001]
  • [Cites] J Biol Chem. 2002 Sep 20;277(38):34967-77 [12087103.001]
  • [Cites] Gene. 2002 Jul 10;294(1-2):1-12 [12234662.001]
  • [Cites] Cancer Sci. 2003 Jan;94(1):9-14 [12708467.001]
  • [Cites] Bioessays. 2003 Jul;25(7):691-8 [12815724.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):27988-96 [12695516.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12384-9 [14530393.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):43470-9 [12917425.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):859-68 [14668816.001]
  • [Cites] Mol Carcinog. 2004 Jan;39(1):34-60 [14694446.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):101-17 [15000152.001]
  • [Cites] Hum Pathol. 2004 Mar;35(3):290-7 [15017584.001]
  • [Cites] Prostate. 2004 May 15;59(3):337-49 [15042610.001]
  • [Cites] J Virol. 2004 Jul;78(14):7478-89 [15220421.001]
  • [Cites] Cell. 1987 Jun 19;49(6):729-39 [3034432.001]
  • [Cites] Cell. 1987 Jun 19;49(6):741-52 [3034433.001]
  • [Cites] Cell. 1988 Mar 11;52(5):705-12 [2830989.001]
  • [Cites] EMBO J. 1989 Jan;8(1):127-32 [2540954.001]
  • [Cites] Biochem Biophys Res Commun. 1996 May 6;222(1):164-70 [8630063.001]
  • [Cites] Ann Oncol. 1996 Feb;7(2):129-33 [8777167.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4224-8 [8797596.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):30089-95 [8939957.001]
  • [Cites] Mol Endocrinol. 1998 Jul;12(7):973-85 [9658402.001]
  • (PMID = 15702969.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA73783; United States / NIEHS NIH HHS / ES / 5 P30 ES09106-03; United States / NCI NIH HHS / CA / R29 CA073783; United States / NIEHS NIH HHS / ES / P30 ES009106; United States / NIEHS NIH HHS / ES / P030ES09106
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Protein Subunits; 0 / RNA, Messenger; 0 / Transcription Factor AP-1; 0 / Y-Box-Binding Protein 1; 0 / YBX1 protein, human; 9007-49-2 / DNA; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.65 / MMP12 protein, human; EC 3.4.24.65 / Matrix Metalloproteinase 12
  • [Other-IDs] NLM/ PMC1183473
  •  go-up   go-down


3. Palefsky J: Human papillomavirus and anal neoplasia. Curr HIV/AIDS Rep; 2008 May;5(2):78-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus and anal neoplasia.
  • Anal cancer is a rare disease in the general population, but the incidence of anal cancer is higher in certain at-risk groups, such as men who have sex with men (MSM), and immunosuppressed individuals, including those with HIV infection.
  • Among HIV-positive MSM, the incidence of anal cancer may be as high as 10 times greater than current rates of cervical cancer in the general population of women.
  • Anal cancer is associated with human papillomavirus (HPV) infection and may be preceded by high-grade anal intraepithelial neoplasia (HGAIN).
  • HGAIN and anal HPV infection are both highly prevalent in groups at risk for anal cancer.
  • Current issues include determining the effect of antiretroviral therapy on the natural history of HGAIN and the incidence of anal cancer, optimizing diagnostic and therapeutic approaches to HGAIN, and determining the potential for prophylactic HPV vaccines to prevent anal HPV infection and anal cancer in at-risk groups.
  • [MeSH-major] Anus Neoplasms. Carcinoma in Situ. Papillomavirus Infections
  • [MeSH-minor] Anus Diseases / epidemiology. Anus Diseases / virology. Female. HIV Infections / complications. Homosexuality, Male. Humans. Male. Papillomaviridae / isolation & purification

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] Nat Med. 2007 Jul;13(7):857-61 [17603495.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):843-9 [11390533.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1221-7 [14520450.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):915-20 [15220697.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1555-9 [14605579.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):1-5 [16133005.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] Virus Res. 1993 Feb;27(2):133-45 [8384765.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] MMWR Recomm Rep. 2004 Dec 17;53(RR-15):1-112 [15841069.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):969-87, ix [17996800.001]
  • [Cites] Transpl Int. 2004 Aug;17(7):366-9 [15349721.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Lancet. 2007 Jun 30;369(9580):2161-2170 [17602732.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):432-42 [11511819.001]
  • [Cites] Br J Dermatol. 2007 Sep;157(3):523-30 [17573882.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Infect Dis. 2004 Nov 1;190(9):1685-91 [15478076.001]
  • [Cites] J Infect Dis. 1990 Aug;162(2):358-61 [1973695.001]
  • [Cites] Cytojournal. 2006 Mar 20;3:4 [16549010.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/140-6 [16950001.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] J Am Acad Dermatol. 2004 Jun;50(6):980-1 [15153912.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):182-9 [16186736.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim [16396154.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]
  • [Cites] Int J Cancer. 1996 Nov 27;68(5):559-64 [8938134.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24 [17380109.001]
  • (PMID = 18510893.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


Advertisement
4. Friederich P, van Heumen BW, Nagtegaal ID, Berkhout M, van Krieken JH, Peters WH, Nagengast FM: Increased epithelial cell proliferation in the ileal pouch mucosa of patients with familial adenomatous polyposis. Virchows Arch; 2007 Sep;451(3):659-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased epithelial cell proliferation in the ileal pouch mucosa of patients with familial adenomatous polyposis.
  • To eliminate the risk of colorectal cancer in patients with familial adenomatous polyposis (FAP), reconstructive proctocolectomy is performed.
  • Although most colonic mucosa is resected during the ileal pouch anal anastomosis, adenomas and carcinomas may develop in the pouch.
  • This may be caused by altered cell kinetics due to intraluminal changes in the pouch.
  • Cell proliferation was also assessed by a modified sign test.
  • However, cell proliferation was significantly higher in the mucosa of the pouch vs afferent ileal loop, both by using the quantitative (68.3% vs 61.6%, p = 0.001) and semiquantitative methods (p < 0.05).
  • The higher cell proliferation in the pouch as compared to the afferent ileal loop may contribute to the increased risk for adenomas and carcinomas in the pouch of patients with FAP and emphasizes the need for regular endoscopic surveillance.
  • [MeSH-major] Adenomatous Polyposis Coli / pathology. Cell Division. Colonic Pouches / pathology. Epithelial Cells / pathology
  • [MeSH-minor] Adenoma / pathology. Adolescent. Adult. Aged. Antibodies, Monoclonal. Apoptosis. Carcinoma / pathology. Colorectal Neoplasms / pathology. Colorectal Neoplasms / prevention & control. Female. Humans. Ileum / pathology. Immunohistochemistry. Intestinal Mucosa / pathology. Male. Middle Aged. Proctocolectomy, Restorative

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Epidemiology. 1996 Sep;7(5):561 [8862998.001]
  • [Cites] Gastroenterology. 1997 Oct;113(4):1159-62 [9322510.001]
  • [Cites] Indian J Cancer. 1997 Mar;34(1):16-9 [9491657.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):552-6; discussion 556-7 [9593235.001]
  • [Cites] J Pathol. 1999 Apr;187(5):567-72 [10398123.001]
  • [Cites] J Gastrointest Surg. 2005 May-Jun;9(5):695-702 [15862266.001]
  • [Cites] Gut. 1999 Dec;45(6):822-8 [10562579.001]
  • [Cites] Gut. 2000 Nov;47(5):732-4 [11034594.001]
  • [Cites] Dis Colon Rectum. 2001 Nov;44(11):1590-6 [11711729.001]
  • [Cites] Gut. 2001 Jan;48(1):41-6 [11115821.001]
  • [Cites] Gut. 2001 Feb;48(2):238-46 [11156647.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):360-4 [11224623.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):347-53 [11289279.001]
  • [Cites] J Infect Dis. 2001 Jul 15;184(2):227-30 [11424022.001]
  • [Cites] Mutat Res. 2001 Sep 1;480-481:129-38 [11506806.001]
  • [Cites] Dis Colon Rectum. 2001 Nov;44(11):1714-5 [11711749.001]
  • [Cites] Lancet. 2003 Jul 19;362(9379):205-9 [12885482.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1418-23; discussion 1422-3 [14530685.001]
  • [Cites] Colorectal Dis. 2003 Nov;5(6):592-4 [14617250.001]
  • [Cites] Gut. 2004 Mar;53(3):381-6 [14960520.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):530-4 [14978621.001]
  • [Cites] Gastroenterology. 1978 Jun;74(6):1325-30 [348556.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):664-8 [4053908.001]
  • [Cites] Gastroenterology. 1987 Mar;92(3):704-8 [3817391.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):4121-6 [3383201.001]
  • [Cites] Gastroenterology. 1989 Mar;96(3):817-24 [2914643.001]
  • [Cites] Dis Colon Rectum. 1989 Dec;32(12):1034-8 [2556253.001]
  • [Cites] J Clin Pathol. 1990 Oct;43(10):824-8 [2172322.001]
  • [Cites] Cancer Res. 1991 Apr 1;51(7):1917-21 [2004376.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1278-88 [1312975.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1144-53 [1397871.001]
  • [Cites] J Pathol. 1992 Dec;168(4):357-63 [1484317.001]
  • [Cites] Br J Surg. 1993 Dec;80(12):1620 [8298944.001]
  • [Cites] Dis Colon Rectum. 1994 Aug;37(8):824-8 [8055729.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):994-8 [7657130.001]
  • [Cites] Br J Surg. 1996 Apr;83(4):506 [8665242.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):995-9 [8712299.001]
  • [Cites] Gut. 1996 Apr;38(4):549-53 [8707086.001]
  • (PMID = 17611772.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  • [Other-IDs] NLM/ PMC2039779
  •  go-up   go-down


5. Li AH, Phanuphak N, Sahasrabuddhe VV, Chaithongwongwatthana S, Vermund SH, Jenkins CA, Shepherd BE, Teeratakulpisarn N, van der Lugt J, Avihingsanon A, Ruxrungtham K, Shikuma C, Phanuphak P, Ananworanich J: Anal squamous intraepithelial lesions among HIV positive and HIV negative men who have sex with men in Thailand. Sex Transm Infect; 2009 Dec;85(7):503-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal squamous intraepithelial lesions among HIV positive and HIV negative men who have sex with men in Thailand.
  • OBJECTIVES: To evaluate the prevalence and risk factors of anal squamous intraepithelial lesions (ASIL), the putative anal cancer precursor, in Asian HIV positive and HIV negative men who have sex with men (MSM).
  • METHODS: Men who underwent anal Pap smear reported clinical, sociodemographic and behavioural information collected through questionnaire and interview between January 2007 and April 2008.
  • Overall, 27% had abnormal anal cytology: 13.2% had atypical squamous cells of undetermined significance (ASC-US), 11.5% had low-grade squamous intraepithelial lesion (LSIL) and 2.3% had high-grade squamous intraepithelial lesion (HSIL).
  • Anal condyloma was detected in 22% of HIV positive and 16.1% (9/56) of HIV negative MSM (p = 0.5).
  • In HIV positive MSM, anal condyloma (OR 3.42, 95% CI 1.29 to 9.04; p = 0.01) was a significant risk factor for ASIL.
  • Highly active antiretroviral therapy use and CD4+ T cell count were not associated with ASIL.
  • Thus, as greater numbers of HIV positive MSM live longer due to increasing access to HAART worldwide, effective strategies to screen and manage anal precancerous lesions are needed.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Carcinoma, Squamous Cell / epidemiology. HIV Seronegativity / physiology. HIV Seropositivity / epidemiology. Homosexuality, Male / statistics & numerical data

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Int J STD AIDS. 2008 Aug;19(8):529-32 [18663038.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):367-73 [12626913.001]
  • [Cites] Am J Epidemiol. 2003 Jun 1;157(11):966-72 [12777359.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Arch Sex Behav. 2004 Apr;33(2):137-47 [15146146.001]
  • [Cites] Clin Infect Dis. 2004 May 15;38(10):1490-2 [15156490.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Infect Dis. 2004 Nov 1;190(9):1685-91 [15478076.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] AIDS. 1993 Jan;7(1):43-9 [8382927.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1757-65 [15541448.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 [15956651.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Aug 11;55(31):844-8 [16902394.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] Sex Transm Dis. 2008 Feb;35(2):197-202 [18216727.001]
  • [Cites] Sex Transm Dis. 2008 Aug;35(8):721-4 [18650771.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • (PMID = 19525263.001).
  • [ISSN] 1472-3263
  • [Journal-full-title] Sexually transmitted infections
  • [ISO-abbreviation] Sex Transm Infect
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI050410; United States / NCRR NIH HHS / RR / TL1 RR024978
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS527353; NLM/ PMC3875384
  •  go-up   go-down


6. Papaconstantinou HT, Lee AJ, Simmang CL, Ashfaq R, Gokaslan ST, Sokol S, Huber PJ Jr, Gregorcyk SG: Screening methods for high-grade dysplasia in patients with anal condyloma. J Surg Res; 2005 Jul 1;127(1):8-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening methods for high-grade dysplasia in patients with anal condyloma.
  • HPV infection can cause anal condylomas and is a risk factor for dysplasia.
  • High-grade dysplasia may progress to squamous cell carcinoma.
  • The purpose of this study is to determine whether anal cytology, morphological characteristics, and/or the presence of high-risk oncogenic HPV-types are effective noninvasive methods to detect high-risk anal condylomas.
  • PATIENTS AND METHODS: From November 2003 to June 2004, all patients with anal condyloma were prospectively evaluated for anal cytology, high-risk oncogenic HPV-types, and tissue biopsies.
  • RESULTS: Forty-seven patients with anal condyloma were studied; 43 (91.5%) were men, and the mean age was 39 +/- 11 years.
  • CONCLUSION: Anal cytology alone is not accurate for detecting HRL in patients with anal condylomas.
  • Combining oncogenic HPV-testing with cytology is more sensitive in detecting HRL in patients with anal condyloma, and therefore, a more effective screening tool.
  • [MeSH-major] Anal Canal / pathology. Anus Diseases / pathology. Anus Neoplasms / pathology. Condylomata Acuminata / pathology. Papillomaviridae. Papillomavirus Infections / pathology. Tumor Virus Infections / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15964301.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Kirillov V, Akimova L: Regression analysis of the initial karyometric data on tumor cells in ductal carcinoma and fibroadenoma of the mammary gland. Anal Quant Cytol Histol; 2010 Apr;32(2):102-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression analysis of the initial karyometric data on tumor cells in ductal carcinoma and fibroadenoma of the mammary gland.
  • OBJECTIVE: To reveal the differences in the parameters of the second order regression curve with a cluster of experimental points on scattergrams showing the dependence of the perimeter on the area of tumor cell nuclei between ductal carcinoma and fibroadenoma of the mammary gland.
  • STUDY DESIGN: Punctate smears taken from patients with ductal carcinoma and fibroadenoma of the mammary gland with coincident histologic and cytologic conclusion were studied and selected.
  • RESULTS: It has been shown that the cluster of experimental points on scattergrams showing the dependence of the perimeter on the area of tumor cell nuclei can be well described by a second order regression curve, which is a parabola.
  • The differences in parabola parameters (coefficients of the parabola equation) characterizing the population of tumor cells in ductal carcinoma and fibroadenoma of the mammary gland were revealed.
  • CONCLUSION: Parameters of the regression curve to a cluster of experimental points on scattergrams showing the dependence of the perimeter on the area of tumor cell nuclei can be used as an additional diagnostic criterion for breast cancer.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701078.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Kouloulias V, Plataniotis G, Kouvaris J, Dardoufas C, Gennatas C, Uzunoglu N, Papavasiliou C, Vlahos L: Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial. Am J Clin Oncol; 2005 Feb;28(1):91-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial.
  • PURPOSE: The purpose of this study was to investigate in a randomized way the clinical benefit of addition of intracavitary hyperthermia (ICHT) to a conventional chemoradiotherapy schedule in patients with T2-T3N0M0 anal cancer.
  • A microwave applicator operating at 433 MHz inserted into the anal-rectal cavity was used for ICHT.
  • CONCLUSION: The addition of ICHT to the chemoradiotherapy schedule of anal cancer seems to offer a new effective and safe therapeutic modality.
  • [MeSH-major] Anus Neoplasms / therapy. Diathermy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15685041.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Cai L, Threadgill MD, Wang Y, Li M: Effect of poly (ADP-ribose) polymerase-1 inhibition on the proliferation of murine colon carcinoma CT26 cells. Pathol Oncol Res; 2009 Sep;15(3):323-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of poly (ADP-ribose) polymerase-1 inhibition on the proliferation of murine colon carcinoma CT26 cells.
  • MTT assays and flow cytometry were used to determine the proliferation and cell cycle distribution, respectively, of the cells.
  • These results suggest that PARP inhibition reduced the proliferation of CT26 cells in vitro and influences the cell cycle.
  • [MeSH-major] Cell Proliferation / drug effects. Colonic Neoplasms / enzymology. Enzyme Inhibitors / pharmacology. NF-kappa B / drug effects. Poly(ADP-ribose) Polymerases / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Cell Cycle. Cell Line, Tumor. Cell Separation. Electrophoretic Mobility Shift Assay. Flow Cytometry. Isoquinolines / pharmacology. Mice. Poly (ADP-Ribose) Polymerase-1

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 2004 Aug;39(8):533-7 [15363352.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6344-8 [15342424.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Jul;289(1):C82-8 [15743888.001]
  • [Cites] Med Sci Monit. 2002 Nov;8(11):BR444-53 [12444369.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8960-7 [15604259.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(14 ):2374-81 [16809031.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2004 Dec;370(6):464-73 [15599708.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 1;350(4):1056-62 [17046715.001]
  • [Cites] Ai Zheng. 2007 Jun;26(6):566-71 [17562258.001]
  • [Cites] Curr Med Chem. 2005;12 (20):2373-92 [16181138.001]
  • [Cites] Cell. 2004 Aug 6;118(3):285-96 [15294155.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):3033-42 [17505006.001]
  • [Cites] Anal Biochem. 1996 May 1;236(2):302-8 [8660509.001]
  • [Cites] Eksp Onkol. 2004 Mar;26(1):40-7 [15112579.001]
  • [Cites] Zhonghua Nei Ke Za Zhi. 2002 Sep;41(9):605-9 [12421493.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Feb;312(2):449-57 [15452194.001]
  • [Cites] Br J Pharmacol. 2000 Jun;130(4):843-50 [10864891.001]
  • [Cites] J Biol Chem. 2004 Oct 8;279(41):42774-86 [15302869.001]
  • [Cites] Biochem Pharmacol. 2002 Jan 15;63(2):293-304 [11841805.001]
  • (PMID = 18989759.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 5-aminoisoquinolinone; 0 / Enzyme Inhibitors; 0 / Isoquinolines; 0 / NF-kappa B; EC 2.4.2.30 / Parp1 protein, mouse; EC 2.4.2.30 / Poly (ADP-Ribose) Polymerase-1; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  •  go-up   go-down


10. Roach SC, Hulse PA, Moulding FJ, Wilson R, Carrington BM: Magnetic resonance imaging of anal cancer. Clin Radiol; 2005 Oct;60(10):1111-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of anal cancer.
  • AIM: The purpose of this study was to evaluate the magnetic resonance imaging (MRI) appearances of primary and recurrent anal carcinoma, and to demonstrate the commonest patterns of local and distant disease spread.
  • METHODS: A retrospective review was performed of 27 cases of biopsy-proven anal carcinoma, where MRI was used for primary staging (9 patients) or suspected recurrence (18 patients).
  • The size, extent and signal characteristics of the anal tumour were documented.
  • Lymph node metastases were of similar signal intensity to the anal cancer.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179172.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Health Quality Ontario: Anal dysplasia screening: an evidence-based analysis. Ont Health Technol Assess Ser; 2007;7(4):1-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal dysplasia screening: an evidence-based analysis.
  • OBJECTIVE: This review considered the role of the anal Pap test as a screening test for anal dysplasia in patients at high risk of anal SCC.
  • CLINICAL NEED: TARGET POPULATION AND CONDITION Anal cancer, like cervical cancer, is a member of a broader group of anogenital cancers known to be associated with sexually transmitted viral HPV infection.
  • Sexual practices involving receptive anal intercourse lead to significantly elevated risk for anal dysplasia and cancer, particularly in those with immune dysfunctions.
  • Anal cancer is rare.
  • It is the least common of the lower gastrointestinal cancers, representing about 4% of them, in contrast to colorectal cancers, which remain the third most commonly diagnosed malignancy.
  • Certain segments of the population, however, such as HIV-positive men and women, other chronic immune-suppressed patients (e.g., after a transplant), injection drug users, and women with genital dysplasia /cancer, have a high susceptibility to anal cancer.
  • Those with the highest identified risk for anal cancer are HIV-positive homosexual and bisexual men, at a rate of 70 per 100,000 men.
  • The risk for anal cancer is reported to be increasing dramatically in HIV-positive males and females, particularly since the introduction of highly active antiretroviral therapy in the mid-1990s.
  • HEALTH TECHNOLOGY DESCRIPTION: Anal Pap test screening involves the blind insertion of a swab into the anal canal and fixing cells either on a slide or in fluid for cytological examination.
  • Anal cytology classified by the standardized Bethesda System is the same classification used for cervical cytology.
  • It has 4 categories: normal, atypical squamous cells of uncertain significance, or squamous intraepithelial lesions which are further classified into low- or high-grade lesions.
  • Unlike cervical cancer, there are no universally accepted guidelines or standards of care for anal dysplasia.
  • The New York State Department of Health AIDS Institute has recently recommended (March 2007) annual anal pap testing in high-risk groups.
  • In Ontario, reimbursement exists only for Pap tests for cervical cancer screening.
  • That is, there is no reimbursement for anal Pap testing in men or women, and HPV screening tests for cervical or anal cancer are also not reimbursed.
  • Assessments of current practices were obtained through consultations with various agencies and individuals including the Ministry of Health and Long-Term Care AIDS Bureau; Public Health Infectious Diseases Branch, Ministry of Health and Long-Term Care; Cancer Care Ontario; HIV/AIDS researchers; pathology experts; and HIV/AIDS clinical program directors.
  • FINDINGS: No direct evidence was found for the existence of controlled studies evaluating the effectiveness of anal Pap test screening programs for impact on anal cancer morbidity or mortality.
  • In addition, no studies were found on the use of HPV DNA testing in the screening or diagnostic setting for anal dysplasia.
  • The reported prevalence of HPV infection in high-risk groups, particularly HIV-positive males, however, was sufficiently high to preclude any utility of HPV testing as an adjunct to anal Pap testing.
  • Nine reports involving studies in the United States, United Kingdom, and Canada were identified that evaluated the performance characteristics of anal Pap test screening for anal dysplasia.
  • Estimates of anal Pap test sensitivity and specificity were highly variable, and depended on the varying prevalence of cytology abnormality and differential thresholds for abnormality for both cytology and histopathology.
  • CONCLUSIONS: No direct evidence exists to support the effectiveness of an anal Pap test screening program to reduce anal cancer mortality or morbidity.
  • There are, however, strong parallels with cervical pap testing for cervical cancer.
  • Sexually transmitted HPV viral infection is currently the acknowledged common causative agent for both anal and cervical cancer.
  • Anal cancer rates in high-risk populations are approaching those of cervical cancer before the implementation of Pap testing.
  • The anal Pap test, although it has been mainly evaluated only in HIV-positive males, has similar operating characteristics of sensitivity and specificity as the cervical Pap test.
  • In general, the treatment options for precancer dysplasia in the cervix and the anus are similar, but treatment involving a definitive surgical resection in the anus is more limited because of the higher risk of complications.
  • A range of ablative therapies has been applied for anal dysplasia, but evidence on treatment effectiveness, tolerability and durability, particularly in the HIV-positive patient, is limited.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1992 Oct 29;327(18):1272-8 [1328880.001]
  • [Cites] Lancet. 1991 Sep 14;338(8768):657-9 [1679474.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]
  • [Cites] JAMA. 1989 Aug 18;262(7):931-4 [2754794.001]
  • [Cites] Am J Epidemiol. 1995 Apr 1;141(7):680-9 [7702044.001]
  • [Cites] J Clin Pathol. 1994 Nov;47(11):1032-4 [7829679.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1238-40 [7953374.001]
  • [Cites] Br J Surg. 1994 Mar;81(3):365-7 [8173899.001]
  • [Cites] Genitourin Med. 1994 Feb;70(1):22-5 [8300094.001]
  • [Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]
  • [Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]
  • [Cites] Gynecol Oncol. 1997 Feb;64(2):213-23 [9038266.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] Obstet Gynecol. 1998 Jun;91(6):973-6 [9611007.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Obstet Gynecol Surv. 1999 Jul;54(7):469-76 [10394585.001]
  • [Cites] J Clin Microbiol. 1999 Aug;37(8):2508-17 [10405393.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] J Clin Microbiol. 2000 Jan;38(1):357-61 [10618116.001]
  • [Cites] Dis Colon Rectum. 2000 Mar;43(3):346-52 [10733116.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):672-81 [10782146.001]
  • [Cites] Ann Intern Med. 2000 May 16;132(10):810-9 [10819705.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Epidemiology. 2000 Jul;11(4):457-61 [10874555.001]
  • [Cites] Drug Saf. 2000 Aug;23(2):101-13 [10945373.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • [Cites] Dis Colon Rectum. 2001 Feb;44(2):236-42 [11227941.001]
  • [Cites] JAMA. 2001 Mar 21;285(11):1500-5 [11255427.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):561-4 [11442593.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/42-51 [16950017.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):516-22 [11520149.001]
  • [Cites] Sex Transm Infect. 2001 Oct;77(5):327-31 [11588276.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):244-65 [11919208.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] J Infect Dis. 2002 May 1;185(9):1229-37 [12001039.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1028-37 [12006515.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):502-7 [12006932.001]
  • [Cites] Int J Colorectal Dis. 2002 Jul;17(4):203-15 [12073068.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Colorectal Dis. 2003 Jul;5(4):353-7 [12814415.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):915-20 [15220697.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Clin Infect Dis. 2004 Sep 1;39(5):609-29 [15356773.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1610-5 [15577418.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1447-56 [15726546.001]
  • [Cites] Br J Surg. 2005 Mar;92(3):277-90 [15736144.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S43-51 [15753011.001]
  • [Cites] Sex Transm Infect. 2005 Apr;81(2):142-6 [15800092.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 [15956651.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1133-6 [16044425.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):1-5 [16133005.001]
  • [Cites] Surg Oncol. 2005 Nov;14(3):121-32 [16165347.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):36-40 [16283561.001]
  • [Cites] Lancet Infect Dis. 2006 Jan;6(1):21-31 [16377531.001]
  • [Cites] Cytojournal. 2006;3:4 [16549010.001]
  • [Cites] Br J Surg. 2006 May;93(5):531-8 [16607677.001]
  • [Cites] AIDS. 2006 May 12;20(8):1151-5 [16691066.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):131-6 [12821353.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):638-42 [12869403.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1103-8; discussion 1108-9 [12907906.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1221-7 [14520450.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1332-6; discussion 1336-8 [14530670.001]
  • [Cites] Cancer. 2004 Feb 25;102(1):19-26 [14968414.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):277-93 [15137957.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):355-73 [15137962.001]
  • [Cites] J Am Acad Dermatol. 2004 Jun;50(6):980-1 [15153912.001]
  • [Cites] Clin Infect Dis. 2004 May 15;38(10):1490-2 [15156490.001]
  • [Cites] BMJ. 2004 Jun 19;328(7454):1490 [15205295.001]
  • (PMID = 23074504.001).
  • [ISSN] 1915-7398
  • [Journal-full-title] Ontario health technology assessment series
  • [ISO-abbreviation] Ont Health Technol Assess Ser
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3377578
  •  go-up   go-down


12. Bartusik D, Tomanek B, Lattová E, Perreault H, Fallone G: Combined treatment of human MCF-7 breast carcinoma with antibody, cationic lipid and hyaluronic acid using ex vivo assays. J Pharm Biomed Anal; 2010 Jan 5;51(1):192-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined treatment of human MCF-7 breast carcinoma with antibody, cationic lipid and hyaluronic acid using ex vivo assays.
  • The effective targeting of malignant cell surface antigens is essential in cancer therapy.
  • Resistance to treatment and rapid invasion of cancer cells are the main causes of cancer mortality.
  • To assess the treatment response, we cultured a 3-D MCF-7 cell line overexpressing HER-2 and CD44 receptors.
  • The high density 3-D cell aggregation in the hollow fiber bioreactor (HFB) used for the cell culture was monitored with the use of proton magnetic resonance imaging ((1)H MRI).
  • The data also demonstrate that HA could be used to enhance treatment efficacy of trastuzumab and anti-HER-2 (clone CB11) in breast cancer cell cultures.
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antigens, CD44 / immunology. Cell Line, Tumor. Cell Survival / drug effects. Chromatography, High Pressure Liquid / methods. DNA / administration & dosage. Drug Resistance, Neoplasm. Drug Synergism. Female. Humans. Hyaluronic Acid / administration & dosage. Lipids / administration & dosage. Magnetic Resonance Imaging / methods. Plasmids / administration & dosage. Receptor, ErbB-2 / immunology. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods. Trastuzumab

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19709839.001).
  • [ISSN] 1873-264X
  • [Journal-full-title] Journal of pharmaceutical and biomedical analysis
  • [ISO-abbreviation] J Pharm Biomed Anal
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD44; 0 / Lipids; 0 / Lipofectamine; 9004-61-9 / Hyaluronic Acid; 9007-49-2 / DNA; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


13. Tougeron D, Tougeron-Brousseau B, Nasser Z, Benzerroug M, Lefebure B, Hamidou H, Michel P, Muraine M: Unusual iris metastasis from anal cancer: a case report. Dig Liver Dis; 2009 Jul;41(7):e1-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual iris metastasis from anal cancer: a case report.
  • We report a case of anal cancer with iris metastasis and summarize the iris metastasis literature.
  • A 69 years old woman with a history of anal cancer presented with a visual field loss.
  • Because of worse prognosis of metastatic cancer and any ocular complications, the patient was treated by radiotherapy which allowed a clinical improvement.
  • A review of medical records was performed to assess the clinical presentation, diagnosis and treatment.
  • Anal carcinoma can metastasize to the iris.
  • [MeSH-major] Anus Neoplasms / pathology. Iris Neoplasms / secondary

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294934.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


14. Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, Frost AR, Louro ID, Townes TM, Paterson AJ, Kudlow JE, Lobo-Ruppert SM, Ruppert JM: Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene; 2005 Feb 24;24(9):1491-500
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia.
  • To examine the role of this zinc finger protein in skin, we expressed the wild-type human allele from inducible and constitutive promoters.
  • KLF4 caused a transitory apoptotic response and the skin progressed through phases of hyperplasia and dysplasia.
  • By 6 weeks, lesions exhibited nuclear KLF4 and other morphologic and molecular similarities to squamous cell carcinoma in situ. p53 determined the patch size sufficient to establish lesions, as induction in a mosaic pattern produced skin lesions only when p53 was deficient.
  • The results suggest that KLF4 can function in the nucleus to induce squamous epithelial dysplasia, and indicate roles for p53 and epithelial-mesenchymal signaling in these early neoplastic lesions.

  • COS Scholar Universe. author profiles.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - FVB.Cg-Tg(tetO-KLF4)32831Rup/Mmjax (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • eagle-i research resources. PMID 15674344 (Special Collections) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):26737-40 [11389134.001]
  • [Cites] Cancer Surv. 1998;32:69-113 [10489624.001]
  • [Cites] Curr Opin Cell Biol. 2001 Dec;13(6):778-84 [11698196.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):418-25 [11694875.001]
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] Development. 2002 Jun;129(11):2619-28 [12015290.001]
  • [Cites] J Invest Dermatol. 2002 Jun;118(6):998-1002 [12060394.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S2-9 [11684435.001]
  • [Cites] Nucleic Acids Res. 1999 Dec 1;27(23):4562-9 [10556311.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):18391-8 [10749849.001]
  • [Cites] Nucleic Acids Res. 2000 Aug 1;28(15):2969-76 [10908361.001]
  • [Cites] J Biol Chem. 2000 Dec 1;275(48):37798-806 [10954723.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6488-95 [11103818.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5867-73 [12384550.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):11661-9 [12538588.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):203-5 [12676578.001]
  • [Cites] Development. 2003 Jun;130(12):2767-77 [12736219.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3424-30 [12776194.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):763-70 [14644203.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Jan;286(1):G23-30 [12919939.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):383-91 [14667505.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):425-9 [14706334.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):395-402 [14724568.001]
  • [Cites] Cell. 2004 Jan 23;116(2):235-46 [14744434.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):311-6 [15093538.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2709-19 [15102675.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3815-24 [15173090.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Cell Sci. 1987 Oct;88 ( Pt 3):305-12 [3129440.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):3713-21 [2660980.001]
  • [Cites] Cell Differ Dev. 1990 Apr;30(1):27-34 [2350734.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1147-55 [2161707.001]
  • [Cites] Nature. 1991 Jul 25;352(6333):345-7 [1852210.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • [Cites] Cell. 1993 Sep 10;74(5):813-22 [8374952.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4477-80 [8402617.001]
  • [Cites] J Virol. 1994 Jul;68(7):4358-68 [7515971.001]
  • [Cites] Nature. 1994 Dec 22-29;372(6508):773-6 [7997263.001]
  • [Cites] Nucleic Acids Res. 1995 May 25;23(10):1686-90 [7784172.001]
  • [Cites] Cancer Metastasis Rev. 1995 Jun;14(2):113-24 [7554029.001]
  • [Cites] Methods Enzymol. 1995;254:3-20 [8531694.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1621-5 [8658135.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] J Cell Biochem. 1995 Dec;59(4):463-72 [8749716.001]
  • [Cites] J Biol Chem. 1996 Aug 16;271(33):20009-17 [8702718.001]
  • [Cites] J Biol Chem. 1996 Dec 6;271(49):31384-90 [8940147.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14025-9 [8943054.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1899-917 [8952526.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):761, 763 [9126728.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254(8):376-83 [9332893.001]
  • [Cites] FEBS Lett. 1997 Dec 15;419(2-3):239-43 [9428642.001]
  • [Cites] J Biol Chem. 1998 Apr 24;273(17):10747-54 [9553140.001]
  • [Cites] J Biol Chem. 1998 Jul 10;273(28):17917-25 [9651398.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):469-86 [9786956.001]
  • [Cites] J Cell Biochem Suppl. 1998;30-31:111-22 [9893262.001]
  • [Cites] Oncogene. 1999 Jun 17;18(24):3593-607 [10380881.001]
  • [Cites] Cell Growth Differ. 1999 Jun;10(6):423-34 [10392904.001]
  • [Cites] Nat Genet. 1999 Aug;22(4):356-60 [10431239.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • (PMID = 15674344.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30CA13148; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / P30 CA013148; United States / NCI NIH HHS / CA / R01 CA094030; United States / NCI NIH HHS / CA / R29 CA065686; United States / NCI NIH HHS / CA / CA89019; United States / NCI NIH HHS / CA / R01 CA065686; United States / NCI NIH HHS / CA / CA65686; United States / NCI NIH HHS / CA / CA094030
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / GKLF protein; 0 / Kruppel-Like Transcription Factors; 0 / Transcription Factors; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ NIHMS7908; NLM/ PMC1361530
  •  go-up   go-down


15. Alix-Panabières C, Vendrell JP, Slijper M, Pellé O, Barbotte E, Mercier G, Jacot W, Fabbro M, Pantel K: Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res; 2009;11(3):R39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer.
  • INTRODUCTION: We evaluated whether CK19, one of the main cytoskeleton proteins of epithelial cells, is released as full-length protein from viable tumor cells and whether this property is relevant for metastatic progression in breast cancer patients.
  • METHODS: EPISPOT (EPithelial ImmunoSPOT) assays were performed to analyze the release of full-length CK19 by carcinoma cells of various origins, and the sequence of CK19 was analyzed with mass spectrometry.
  • CK19-EPISPOT was used to detect disseminated tumor cells in bone marrow (BM) of 45 breast cancer patients who were then followed up over a median of 6 years.
  • RESULTS: CK19 was expressed and released by colorectal (HT-29, HCT116, Caco-2) and breast (MCF-7, SKBR3, and MDA-MB-231) cancer cell lines.
  • Functional experiments indicated that CK19 release was an active process and not simply the consequence of cell death.
  • CK19-releasing cells (RCs) were detectable in BM of 44% to 70% of breast cancer patients.
  • CONCLUSIONS: Full-length CK19 is released by viable epithelial tumor cells, and CK19-RCs might constitute a biologically active subset of breast cancer cells with high metastatic properties.
  • [MeSH-minor] Adult. Aged. Bone Marrow Cells / metabolism. Cell Line, Tumor. Disease Progression. Epithelial Cells / metabolism. Epitopes. Female. Humans. Middle Aged. Multivariate Analysis. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Cell Biol. 2002 Feb;14(1):110-22 [11792552.001]
  • [Cites] Breast Cancer Res Treat. 2009 Sep;117(1):219-21 [18853248.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] J Cell Biochem. 2002;85(4):670-7 [11968007.001]
  • [Cites] Anal Chem. 2003 Feb 1;75(3):663-70 [12585499.001]
  • [Cites] Cell Prolif. 2003 Oct;36 Suppl 1:33-44 [14521514.001]
  • [Cites] Mol Cell Proteomics. 2004 Jan;3(1):73-81 [14593079.001]
  • [Cites] Trends Endocrinol Metab. 2004 Jul;15(5):193-7 [15223047.001]
  • [Cites] Cancer Detect Prev. 1983;6(1-2):41-50 [6883392.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):109-21 [6361139.001]
  • [Cites] J Submicrosc Cytol. 1985 Jul;17(3):357-61 [2410624.001]
  • [Cites] Can J Biochem Cell Biol. 1985 Jun;63(6):680-90 [2412674.001]
  • [Cites] N Engl J Med. 2000 Feb 24;342(8):525-33 [10684910.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):2241-3 [10928185.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3117-22 [10955792.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):468-73 [11251967.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1890-5 [11280743.001]
  • [Cites] Int J Oncol. 2002 Jan;20(1):31-7 [11743639.001]
  • [Cites] Eur J Cell Biol. 1988 Dec;47(2):300-19 [2468493.001]
  • [Cites] Cancer Res. 1993 Jan 1;53(1):61-6 [7677981.001]
  • [Cites] J Virol. 1994 Aug;68(8):4857-61 [8035484.001]
  • [Cites] Annu Rev Biochem. 1994;63:345-82 [7979242.001]
  • [Cites] Eur J Biochem. 1995 Jul 15;231(2):475-85 [7543411.001]
  • [Cites] Nat Med. 1995 Oct;1(10):1035-9 [7489359.001]
  • [Cites] J Biol Chem. 1997 Dec 26;272(52):33197-203 [9407108.001]
  • [Cites] J Pathol. 1999 Apr;187(5):567-72 [10398123.001]
  • [Cites] J Immunol Methods. 2005 Apr;299(1-2):177-88 [15914200.001]
  • [Cites] Clin Chem. 2005 Aug;51(8):1538-41 [16040853.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):793-802 [16120859.001]
  • [Cites] Nature. 2006 May 18;441(7091):362-5 [16710422.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17361-5 [17079488.001]
  • [Cites] Clin Chem. 2007 Mar;53(3):537-9 [17327507.001]
  • [Cites] Nat Rev Cancer. 2008 May;8(5):329-40 [18404148.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3646-50 [18559576.001]
  • [Cites] Methods Mol Biol. 2008;484:97-109 [18592175.001]
  • [Cites] J Proteome Res. 2008 Jul;7(7):3060-3 [18494517.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5013-21 [18698019.001]
  • [Cites] J Natl Cancer Inst. 2009 Jan 7;101(1):61-6 [19116383.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):267-8 [19383302.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Jun;6(6):339-51 [19399023.001]
  • [Cites] Genes Dev. 2002 Mar 15;16(6):693-706 [11914275.001]
  • (PMID = 19549321.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Epitopes; 0 / Keratin-19
  • [Other-IDs] NLM/ PMC2716508
  •  go-up   go-down


16. Tajiri M, Kameda Y, Nakayama H, Sakamoto K: Prognosis and morphometrical features of non-bronchioloalveolar cell adenocarcinoma: an assessment of the non-alveolar replacing area and high grade atypical area. J Clin Pathol; 2006 Mar;59(3):269-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis and morphometrical features of non-bronchioloalveolar cell adenocarcinoma: an assessment of the non-alveolar replacing area and high grade atypical area.
  • AIM: It has become obvious that the prognosis of bronchioloalveolar cell carcinoma (BAC) in small peripheral adenocarcinoma of the lung is good, but most cases actually treated as pulmonary adenocarcinoma in hospitals tend to be non-bronchioloalveolar cell carcinoma (non-BAC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 1999 Dec;68(6):2069-73 [10616979.001]
  • [Cites] Ann Thorac Surg. 2000 Mar;69(3):893-7 [10750779.001]
  • [Cites] Lung Cancer. 2000 Sep;29(3):179-88 [10996420.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7950-4 [11691817.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):937-51 [12826886.001]
  • [Cites] Am J Clin Pathol. 1999 May;111(5):610-22 [10230351.001]
  • [Cites] Anal Quant Cytol. 1982 Sep;4(3):225-32 [7149488.001]
  • [Cites] Mod Pathol. 1990 May;3(3):314-20 [2362938.001]
  • [Cites] Am J Surg Pathol. 1990 Oct;14(10):904-12 [2403196.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Am J Surg Pathol. 1996 May;20(5):553-62 [8619420.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):198-206 [15043309.001]
  • (PMID = 16505277.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860342
  •  go-up   go-down


17. Wu M, Jung L, Cooper AB, Fleet C, Chen L, Breault L, Clark K, Cai Z, Vincent S, Bottega S, Shen Q, Richardson A, Bosenburg M, Naber SP, DePinho RA, Kuperwasser C, Robinson MO: Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice. Proc Natl Acad Sci U S A; 2009 Apr 28;106(17):7022-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice.
  • Breast cancer development is a complex pathobiological process involving sequential genetic alterations in normal epithelial cells that results in uncontrolled growth in a permissive microenvironment.
  • Accordingly, physiologically relevant models of human breast cancer that recapitulate these events are needed to study cancer biology and evaluate therapeutic agents.
  • Here, we report the generation and utilization of the human breast cancer in mouse (HIM) model, which is composed of genetically engineered primary human breast epithelial organoids and activated human breast stromal cells.
  • Tumor development in the HIM model proceeds through defined histological stages of hyperplasia, DCIS to invasive carcinoma.
  • The HIM model is an experimentally tractable human in vivo system that holds great potential for advancing our basic understanding of cancer biology and for the discovery and testing of targeted therapies.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):415-8 [11920593.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 1:S15-9 [11521715.001]
  • [Cites] Endocrinology. 2002 Dec;143(12):4886-96 [12446616.001]
  • [Cites] Cancer Cell. 2003 May;3(5):483-95 [12781366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2003;21:223-33 [15338747.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5291-8 [1394133.001]
  • [Cites] Anal Quant Cytol Histol. 1992 Dec;14(6):433-45 [1363346.001]
  • [Cites] J Biol Chem. 1996 Mar 29;271(13):7673-8 [8631805.001]
  • [Cites] Pathol Int. 1998 Jul;48(7):518-25 [9701014.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Oct 20;251(2):609-12 [9792821.001]
  • [Cites] Genes Dev. 1999 Sep 15;13(18):2388-99 [10500096.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7678-81 [15520168.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2460-8 [15710948.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):741-54 [16915232.001]
  • [Cites] Hum Pathol. 2008 Feb;39(2):167-74 [18045647.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Oct 15;114(2):154-5 [10549274.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Genes Dev. 2001 Jan 1;15(1):50-65 [11156605.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Am J Nurs. 2001 Apr;101(4):11 [11301675.001]
  • [Cites] Science. 2002 Apr 19;296(5567):550-3 [11910072.001]
  • (PMID = 19369208.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.7.49 / Telomerase; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


18. Gorjala P, Gary RK: Beryllium sulfate induces p21 CDKN1A expression and a senescence-like cell cycle arrest in susceptible cancer cell types. Biometals; 2010 Dec;23(6):1061-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beryllium sulfate induces p21 CDKN1A expression and a senescence-like cell cycle arrest in susceptible cancer cell types.
  • It is not known whether Be(2+) can affect the proliferation of cancer cells, which are generally unsusceptible to senescence.
  • A172 glioblastoma and RKO colon carcinoma cell lines each have wildtype p53, so these cell types have the potential to be responsive to agents that activate p53.
  • In A172 cells, BeSO(4) produced a G(0)/G(1)-phase cell cycle arrest and increased expression of senescence-associated β-galactosidase, an enzymatic marker of senescence.
  • In contrast, BeSO(4) had no effect on RKO cells, even though Be(2+) uptake was similar for the two cell types.

  • Hazardous Substances Data Bank. BERYLLIUM SULFATE .
  • Hazardous Substances Data Bank. BERYLLIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Dec 13;18(53):7644-55 [10618704.001]
  • [Cites] Radiat Res. 2005 Jan;163(1):53-62 [15606307.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1186-92 [15533933.001]
  • [Cites] Int J Biochem Cell Biol. 2005 May;37(5):961-76 [15743671.001]
  • [Cites] Anal Biochem. 2005 Aug 15;343(2):329-34 [16004951.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):976-81 [16418264.001]
  • [Cites] Biotechniques. 2006 Feb;40(2):173-7 [16526406.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Jul;322(1):70-9 [17395767.001]
  • [Cites] Ann Allergy Asthma Immunol. 2008 Apr;100(4):333-7 [18450118.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1485-95 [18640498.001]
  • [Cites] J Biomed Mater Res A. 2008 Sep 15;86(4):905-13 [18050301.001]
  • [Cites] Cell Cycle. 2008 Aug 15;7(16):2535-43 [18719376.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1713-22 [10669748.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2803-8 [10733583.001]
  • [Cites] Cancer Lett. 2000 Dec 20;161(2):141-7 [11090962.001]
  • [Cites] FEBS Lett. 2001 Feb 16;490(3):117-22 [11223026.001]
  • [Cites] Gene Ther. 2000 Dec;7(24):2071-9 [11223987.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1493-9 [11245456.001]
  • [Cites] Toxicology. 2001 Mar 7;160(1-3):119-27 [11246132.001]
  • [Cites] Eur J Biochem. 2001 May;268(10):2784-91 [11358493.001]
  • [Cites] Mol Cell Biochem. 2001 Jun;222(1-2):69-76 [11678613.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3207-12 [12082636.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):99-105 [14643414.001]
  • [Cites] Mol Cell. 2004 May 21;14(4):501-13 [15149599.001]
  • [Cites] Radiat Res. 2004 May;161(5):504-10 [15161374.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3748-52 [15172978.001]
  • [Cites] Biochem J. 1968 Feb;106(4):811-20 [5637364.001]
  • [Cites] Chem Biol Interact. 1979 Jul;26(2):167-77 [455565.001]
  • [Cites] Environ Res. 1982 Feb;27(1):150-8 [7067673.001]
  • [Cites] Mutat Res. 1990 Mar;240(3):217-25 [2179717.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 1;90(9):3988-92 [8387205.001]
  • [Cites] Mol Cell Biol. 1993 Jul;13(7):4242-50 [8321226.001]
  • [Cites] Exp Cell Res. 1994 Mar;211(1):90-8 [8125163.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] BMJ. 1996 Apr 27;312(7038):1079 [8616417.001]
  • [Cites] Mutat Res. 1996 Nov 4;371(1-2):1-13 [8950345.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 1;37(1):145-54 [9054890.001]
  • [Cites] J Clin Pathol. 1997 Feb;50(2):106-9 [9155689.001]
  • [Cites] Mol Carcinog. 1997 Aug;19(4):243-53 [9290701.001]
  • [Cites] Cell. 1997 Oct 31;91(3):325-34 [9363941.001]
  • [Cites] Mol Cell Biol. 1998 Mar;18(3):1400-7 [9488455.001]
  • [Cites] Mol Cell Biol. 1998 Mar;18(3):1611-21 [9488478.001]
  • [Cites] EMBO J. 1998 Sep 1;17(17):5001-14 [9724636.001]
  • [Cites] J Biol Chem. 1999 Feb 5;274(6):3565-72 [9920903.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):2109-17 [10022898.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(3):760-9 [10629032.001]
  • (PMID = 20549306.001).
  • [ISSN] 1572-8773
  • [Journal-full-title] Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine
  • [ISO-abbreviation] Biometals
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016464; United States / NCRR NIH HHS / RR / RR016464-077332; United States / NCRR NIH HHS / RR / P20 RR-016464; United States / NCRR NIH HHS / RR / P20 RR016464-077332
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Tumor Suppressor Protein p53; 01UQ1KPC7E / beryllium sulfate; EC 3.2.1.23 / beta-Galactosidase; OW5102UV6N / Beryllium
  • [Other-IDs] NLM/ NIHMS223050; NLM/ PMC2976805
  •  go-up   go-down


19. Muggerud AA, Johnsen H, Barnes DA, Steel A, Lønning PE, Naume B, Sørlie T, Børresen-Dale AL: Evaluation of MetriGenix custom 4D arrays applied for detection of breast cancer subtypes. BMC Cancer; 2006;6:59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of MetriGenix custom 4D arrays applied for detection of breast cancer subtypes.
  • BACKGROUND: Previously, a total of five breast cancer subtypes have been identified based on variation in gene expression patterns.
  • In this study tumour samples from 27 breast cancer patients, previously subtyped by expression analysis using DNA microarrays, and four controls from normal breast tissue were included.
  • METHODS: We applied MetriGenix custom 4D arrays for the detection of previously defined molecular subtypes of breast cancer.
  • [MeSH-major] Breast Neoplasms / classification. Carcinoma / classification. Gene Expression Profiling / methods. Oligonucleotide Array Sequence Analysis / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytogenet Cell Genet. 1999;87(1-2):47-52 [10640810.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Anal Chem. 2001 Jun 1;73(11):2412-20 [11403280.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Anal Chem. 2001 Dec 15;73(24):5777-83 [11791544.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2170-8 [15781628.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5582-8 [14654539.001]
  • [Cites] Mol Biol Cell. 2004 Jun;15(6):2523-36 [15034139.001]
  • [Cites] Expert Rev Mol Diagn. 2001 May;1(1):81-91 [11901803.001]
  • (PMID = 16536878.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1421426
  •  go-up   go-down


20. Cortés-Gutiérrez EI, Dávila-Rodríguez MI, Zamudio-González EA, Aguado-Barrera ME, Vargas-Villarreal J, Cerda-Flores RM: DNA damage in Mexican women with cervical dysplasia evaluated by comet assay. Anal Quant Cytol Histol; 2010 Aug;32(4):207-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DNA damage levels (none, low, medium and high) in the cervical epithelial cells of 31 women (10 with low grade squamous intraepithelial lesions [LSIL], 10 with high grade [HSIL] and 11 with no cervical lesion) were evaluated using the comet assay.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21434521.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Matsopoulos GK, Mouravliansky NA, Asvestas PA, Delibasis KK, Kouloulias V: Thoracic non-rigid registration combining self-organizing maps and radial basis functions. Med Image Anal; 2005 Jun;9(3):237-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An automatic three-dimensional non-rigid registration scheme is proposed in this paper and applied to thoracic computed tomography (CT) data of patients with stage III non-small cell lung cancer (NSCLC).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiography. Imaging, Three-Dimensional / methods. Lung Neoplasms / radiography. Pattern Recognition, Automated / methods. Radiographic Image Interpretation, Computer-Assisted / methods. Radiography, Thoracic / methods. Subtraction Technique

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854844.001).
  • [ISSN] 1361-8415
  • [Journal-full-title] Medical image analysis
  • [ISO-abbreviation] Med Image Anal
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Subramanian N, Pichon E, Solomon SB: Automatic registration using implicit shape representations: applications in intraoperative 3D rotational angiography to preoperative CTA registration. Int J Comput Assist Radiol Surg; 2009 Mar;4(2):141-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Angiography / methods. Carcinoma, Hepatocellular / diagnostic imaging. Imaging, Three-Dimensional / methods. Liver Neoplasms / diagnostic imaging. Tomography, X-Ray Computed / methods. User-Computer Interface

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Image Anal. 2006 Jun;10(3):452-64 [15979375.001]
  • [Cites] Acad Radiol. 2007 Nov;14 (11):1325-40 [17964457.001]
  • (PMID = 20033612.001).
  • [ISSN] 1861-6429
  • [Journal-full-title] International journal of computer assisted radiology and surgery
  • [ISO-abbreviation] Int J Comput Assist Radiol Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, Klein D, Quesenberry CP Jr, Towner WJ, Abrams DI: HIV infection and the risk of cancers with and without a known infectious cause. AIDS; 2009 Nov 13;23(17):2337-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV infection and the risk of cancers with and without a known infectious cause.
  • OBJECTIVE: To evaluate the risk of cancers with and without a known infectious cause in HIV-infected persons.
  • METHODS: Adult HIV-infected and matched HIV-uninfected members of Kaiser Permanente followed between 1996 and 2007 for incident AIDS-defining cancers (ADCs), infection-related non-AIDS-defining cancers (NADCs; anal squamous cell, vagina/vulva, Hodgkin's lymphoma, penis, liver, human papillomavirus-related oral cavity/pharynx, stomach) and infection-unrelated NADC (all other NADCs).
  • These results were largely influenced by anal squamous cell cancer and Hodgkin's lymphoma.
  • Among infection-unrelated NADCs, other anal, skin, other head and neck, and lung cancer rates were higher and prostate cancer rates lower in HIV-infected persons.
  • Among all infection-unrelated NADCs, the rate ratio decreased over time only for lung cancer (P = 0.007).
  • CONCLUSION: In comparison with those without HIV infection, HIV-infected persons are at particular risk for cancers with a known infectious cause, although the higher risk has decreased in the antiretroviral therapy era.
  • Cancers without a known infectious cause are modestly increased in HIV-infected persons compared with HIV-uninfected persons.


24. Nelson H: Mayo Clinic office visit. Anal cancer. An interview with Heidi Nelson, M.D. Mayo Clin Womens Healthsource; 2009 Dec;13(12):6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mayo Clinic office visit. Anal cancer. An interview with Heidi Nelson, M.D.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Health Knowledge, Attitudes, Practice. Patient Education as Topic

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19881450.001).
  • [ISSN] 1091-0220
  • [Journal-full-title] Mayo Clinic women's healthsource
  • [ISO-abbreviation] Mayo Clin Womens Healthsource
  • [Language] eng
  • [Publication-type] Interview
  • [Publication-country] United States
  •  go-up   go-down


25. Mi Y, Lou L: ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. Br J Cancer; 2007 Oct 8;97(7):934-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • P-glycoprotein (P-gp) pumps multiple types of drugs out of the cell, using energy generated from ATP, and confers multidrug resistance (MDR) on cancer cells.
  • This study was designed to examine whether ZD6474 reverses P-gp-mediated MDR in cancer cells.
  • Here, we show that clinically achievable levels of ZD6474 reverse P-gp-mediated MDR of the P-gp-overexpressing cell lines derived from breast cancer, MCF-7/adriamycin (ADR), and human oral epidermoid carcinoma, KBV200 to ADR, docetaxel, and vinorelbine.
  • Our results suggest that ZD6474 is capable of reversing MDR in cancer cells by directly inhibiting the function of P-gp, a finding that may have clinical implications for ZD6474.
  • [MeSH-major] Cell Proliferation / drug effects. Drug Resistance, Multiple / drug effects. Drug Resistance, Neoplasm / drug effects. P-Glycoprotein / antagonists & inhibitors. Piperidines / pharmacology. Quinazolines / pharmacology

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Mar 23;276(12):8657-64 [11121420.001]
  • [Cites] Mol Cancer Ther. 2006 Jul;5(7):1883-94 [16891475.001]
  • [Cites] EMBO J. 2001 Oct 15;20(20):5615-25 [11598005.001]
  • [Cites] J Bioenerg Biomembr. 2001 Dec;33(6):503-11 [11804192.001]
  • [Cites] Anal Biochem. 2002 Jun 1;305(1):106-14 [12018951.001]
  • [Cites] Annu Rev Biochem. 2002;71:537-92 [12045106.001]
  • [Cites] Biochim Biophys Acta. 2002 Jul 18;1587(2-3):318-25 [12084474.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1546-56 [12684431.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7340-58 [14576842.001]
  • [Cites] Mol Pharmacol. 2004 Jun;65(6):1485-95 [15155841.001]
  • [Cites] Biochem Pharmacol. 2004 Sep 1;68(5):843-55 [15294447.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1385-7 [1878599.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):152-8 [7903202.001]
  • [Cites] Biochem J. 1996 Jul 15;317 ( Pt 2):515-22 [8713080.001]
  • [Cites] Ann Oncol. 2005 May;16 Suppl 4:iv61-68 [15923432.001]
  • [Cites] Br J Cancer. 2005 Jun;92 Suppl 1:S6-13 [15928657.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4852-60 [15930306.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1391-7 [15905307.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6943-9 [16061679.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):337-43 [15955594.001]
  • [Cites] Semin Oncol. 2006 Feb;33(1 Suppl 1):S9-16 [16472704.001]
  • [Cites] Cell Mol Life Sci. 2001 Jun;58(7):931-59 [11497241.001]
  • (PMID = 17912240.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / P-Glycoprotein; 0 / Piperidines; 0 / Quinazolines; 1N3CZ14C5O / Rhodamine 123; 80168379AG / Doxorubicin; EC 3.6.1.- / Adenosine Triphosphatases
  • [Other-IDs] NLM/ PMC2360411
  •  go-up   go-down


26. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, Brooks JT, Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med; 2008 May 20;148(10):728-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003.
  • BACKGROUND: Persons who are HIV-infected may be at higher risk for certain types of cancer than the general population.
  • OBJECTIVE: To compare cancer incidence among HIV-infected persons with incidence in the general population from 1992 to 2003.
  • PATIENTS: 54,780 HIV-infected persons in the Adult and Adolescent Spectrum of HIV Disease Project (47,832 patients) and the HIV Outpatient Study (6948 patients), who contributed 157,819 person-years of follow-up from 1992 to 2003, and 334,802,121 records from the Surveillance, Epidemiology, and End Results program of 13 geographically defined, population-based, central cancer registries.
  • MEASUREMENTS: Standardized rate ratios (SRRs) to compare cancer incidence in the HIV-infected population with standardized cancer incidence in the general population.
  • RESULTS: The incidence of the following types of non-AIDS-defining cancer was significantly higher in the HIV-infected population than in the general population: anal (SRR, 42.9 [95% CI, 34.1 to 53.3]), vaginal (21.0 [CI, 11.2 to 35.9]), Hodgkin lymphoma (14.7 [CI, 11.6 to 18.2]), liver (7.7 [CI, 5.7 to 10.1]), lung (3.3 [CI, 2.8 to 3.9]), melanoma (2.6 [CI, 1.9 to 3.6]), oropharyngeal (2.6 [CI, 1.9 to 3.4]), leukemia (2.5 [CI, 1.6 to 3.8]), colorectal (2.3 [CI, 1.8 to 2.9]), and renal (1.8 [CI, 1.1 to 2.7]).
  • The incidence of prostate cancer was significantly lower among HIV-infected persons than the general population (SRR, 0.6 [CI, 0.4 to 0.8]).
  • Only the relative incidence of anal cancer increased over time.
  • LIMITATIONS: Lower ascertainment of cancer in the HIV cohorts may result in a potential bias to underestimate rate disparities.
  • Tobacco use as a risk factor and the effect of changes in cancer screening practices could not be evaluated.
  • CONCLUSION: The incidence of many types of non-AIDS-defining cancer was higher among HIV-infected persons than among the general population from 1992 to 2003.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Incidence. Male. Middle Aged. Observation. Prospective Studies. Risk Factors. Tobacco Use Disorder / complications. United States / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [SummaryForPatientsIn] Ann Intern Med. 2008 May 20;148(10):I46 [18490669.001]
  • (PMID = 18490686.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Grant] United States / PHS HHS / / 200-2006-18797
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Investigator] Thompson M; Sinclair E; Cohen D; Davidson A; Rietmeijer C; Garland W; Wohl A; Morse A; Wotring L; Mokotoff E; Murrill C; Bernard MA; Amill A; de los Angeles Gomez M; Miranda S; Buskin S; Barash E; Odem S; Keiser P; Awosika-Olumo A; Wood KC; Baker RK; Palella FJ; Chmiel JS; Cheley J; Lichtenstein KA; Greenberg KS; Young B; Widick B; Stewart C; Zellner P; Yangco BG; Halkias K; Ward DJ; Fiorentino CA; Ording-Bauer L; Kelly R; Esteves J; Tedaldi EM; Christian R; Ruley F; Marzouk JB; Phelps RT; Rachel M; McCabe RE; Rachel M; Novak RM; Uy JP; Wendrow A
  •  go-up   go-down


27. Gao Y, Hu N, Han X, Giffen C, Ding T, Goldstein AM, Taylor PR: Jasmine tea consumption and upper gastrointestinal cancer in China. Cancer Causes Control; 2009 Dec;20(10):1997-2007
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jasmine tea consumption and upper gastrointestinal cancer in China.
  • INTRODUCTION: Epidemiological data on green/jasmine tea and esophageal as well as gastric cancer are limited and inconclusive.
  • METHODS: In order to study the effect of jasmine tea in upper gastrointestinal (UGI) cancers, we evaluated 600 esophageal squamous cell carcinoma (ESCC), 598 gastric cardia cancer (GCA), and 316 gastric non-cardia cancer (GNCA) cases and 1,514 age-, gender-, and neighborhood-matched controls.
  • CONCLUSION: Overall, we found no evidence for a protective effect of tea in esophageal or gastric cancer.
  • Further studies of the potential effects of thermal damage, tea quality, and water quality on UGI cancers are suggested.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Drinking Behavior / physiology. Gastrointestinal Neoplasms / etiology. Jasminum. Plant Preparations. Tea

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Green tea .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Analyst. 1998 Oct;123(10):2145-8 [10209900.001]
  • [Cites] Curr Drug Metab. 2006 Oct;7(7):755-809 [17073579.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):456-63 [15455378.001]
  • [Cites] Food Chem Toxicol. 2005 Jan;43(1):41-8 [15582194.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):193-200 [15498792.001]
  • [Cites] J Agric Food Chem. 2004 Dec 29;52(26):8268-71 [15612828.001]
  • [Cites] Mol Nutr Food Res. 2007 Jan;51(1):116-34 [17195249.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2007 Feb;19(2):171-6 [17273005.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):725-32 [17550753.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 15;853(1-2):154-62 [17400037.001]
  • [Cites] Phytomedicine. 2007 Aug;14(7-8):551-5 [17092697.001]
  • [Cites] J Cell Biochem. 2008 Feb 1;103(2):509-19 [17570133.001]
  • [Cites] J Clin Gastroenterol. 2008 May-Jun;42(5):610-9 [18364578.001]
  • [Cites] Int J Cancer. 2009 Feb 1;124(3):670-7 [18973231.001]
  • [Cites] BMJ. 2009;338:b929 [19325180.001]
  • [Cites] Nat Rev Cancer. 2009 Jun;9(6):429-39 [19472429.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1999 Apr;20(2):95-7 [10682542.001]
  • [Cites] Int J Cancer. 2000 Nov 15;88(4):658-64 [11058886.001]
  • [Cites] Br J Cancer. 2001 Nov 30;85(11):1667-70 [11742485.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 2001 Dec;22(6):442-5 [11851060.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Feb;29 Suppl 1:159-72 [11890101.001]
  • [Cites] Anal Sci. 2002 Mar;18(3):313-8 [11918191.001]
  • [Cites] FASEB J. 2002 Sep;16(11):1463-4 [12205049.001]
  • [Cites] World J Gastroenterol. 2003 Jun;9(6):1187-90 [12800221.001]
  • [Cites] Chemosphere. 2003 Sep;52(9):1475-82 [12867178.001]
  • [Cites] Asian Pac J Cancer Prev. 2003 Apr-Jun;4(2):119-24 [12875624.001]
  • [Cites] Zhonghua Yu Fang Yi Xue Za Zhi. 2003 May;37(3):171-3 [12880562.001]
  • [Cites] Carcinogenesis. 2003 Aug;24(8):1369-78 [12819184.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7563-70 [14633667.001]
  • [Cites] Mutat Res. 2004 Mar 22;547(1-2):55-62 [15013699.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):630-7 [15286742.001]
  • [Cites] Gut. 1972 Jan;13(1):24-30 [5060664.001]
  • [Cites] Int J Cancer. 1974 Mar 15;13(3):291-303 [4822104.001]
  • [Cites] Sci Sin. 1975 Jan-Feb;18(1):131-48 [1145176.001]
  • [Cites] Br J Cancer. 1979 Mar;39(3):293-309 [465299.001]
  • [Cites] Biomed Environ Sci. 1990 Mar;3(1):35-42 [2331325.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1991 Aug;12(4):200-4 [1934041.001]
  • [Cites] Biomed Environ Sci. 1991 Sep;4(3):225-31 [1764211.001]
  • [Cites] Prev Med. 1992 May;21(3):385-91 [1615000.001]
  • [Cites] Int J Cancer. 1994 Apr 1;57(1):38-46 [8150539.001]
  • [Cites] J Natl Cancer Inst. 1994 Jun 1;86(11):855-8 [8182766.001]
  • [Cites] Am J Ind Med. 1995 May;27(5):749-57 [7611309.001]
  • [Cites] J Epidemiol. 1998 Oct;8(4):235-43 [9816815.001]
  • [Cites] Am J Ind Med. 1999 Mar;35(3):272-80 [9987560.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Epidemiol. 2005 Jun;15 Suppl 2:S109-12 [16127221.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):8049-56 [16140980.001]
  • [Cites] Environ Monit Assess. 2005 Aug;107(1-3):399-406 [16418925.001]
  • [Cites] Environ Sci Technol. 2006 Feb 15;40(4):1133-8 [16572766.001]
  • [Cites] J Agric Food Chem. 2006 Jun 14;54(12):4350-4 [16756366.001]
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):4033-7 [16810754.001]
  • [Cites] J Food Prot. 2006 Aug;69(8):2024-8 [16924937.001]
  • [Cites] J Epidemiol. 2006 Sep;16(5):185-92 [16951537.001]
  • [Cites] Asian Pac J Cancer Prev. 2006 Jul-Sep;7(3):375-80 [17059325.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):475-82 [15455377.001]
  • (PMID = 19597950.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP000185-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Plant Preparations; 0 / Tea
  • [Other-IDs] NLM/ NIHMS339598; NLM/ PMC3236106
  •  go-up   go-down


28. Taub AF: Photodynamic therapy: other uses. Dermatol Clin; 2007 Jan;25(1):101-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mainstream uses for photodynamic therapy (PDT) in dermatology include nonmelanoma skin cancer and its precursors, acne vulgaris, photorejuvenation, and hidradenitis suppurativa.
  • Many other dermatologic entities have been treated with PDT, including psoriasis, lichen planus, lichen sclerosus, scleroderma, cutaneous T cell lymphoma, alopecia areata, verruca vulgaris, Darier's disease and tinea infections.
  • Nondermatologic applications include anal and vulva carcinoma, palliation of metastatic breast cancer to skin, Barrett's esophagus, and macular degeneration of the retina.
  • PDT also has found to be useful in immunologic and inflammatory disorders, neoplasias other than skin cancer, and infections.
  • [MeSH-major] Infection / drug therapy. Neoplasms / drug therapy. Photochemotherapy. Skin Diseases / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126748.001).
  • [ISSN] 0733-8635
  • [Journal-full-title] Dermatologic clinics
  • [ISO-abbreviation] Dermatol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


29. Asolkar RN, Freel KC, Jensen PR, Fenical W, Kondratyuk TP, Park EJ, Pezzuto JM: Arenamides A-C, cytotoxic NFkappaB inhibitors from the marine actinomycete Salinispora arenicola. J Nat Prod; 2009 Mar 27;72(3):396-402
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moderate cytotoxicity was observed with the human colon carcinoma cell line HCT-116, but no cytotoxic effect was noted with cultured RAW cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Cycle. 2008 Apr 15;7(8):1020-35 [18414053.001]
  • [Cites] J Am Chem Soc. 2008 Apr 2;130(13):4507-16 [18331040.001]
  • [Cites] Phytochemistry. 2002 Nov;61(6):693-8 [12423891.001]
  • [Cites] Methods Enzymol. 2008;441:329-38 [18554543.001]
  • [Cites] J Antibiot (Tokyo). 1999 Oct;52(10):873-9 [10604756.001]
  • [Cites] Annu Rev Immunol. 2000;18:621-63 [10837071.001]
  • [Cites] Biol Reprod. 2002 Aug;67(2):668-73 [12135912.001]
  • [Cites] Anal Biochem. 1982 Oct;126(1):131-8 [7181105.001]
  • [Cites] J Nat Prod. 1992 May;55(5):613-9 [1517734.001]
  • [Cites] Phytochemistry. 1994 Nov;37(5):1301-3 [7765754.001]
  • [Cites] Planta Med. 2006 Feb;72(3):255-60 [16534731.001]
  • [Cites] J Nat Prod. 2006 Mar;69(3):421-4 [16562850.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):779-84 [16530406.001]
  • [Cites] Cell Death Differ. 2006 May;13(5):738-47 [16485028.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):666-73 [17108984.001]
  • [Cites] Expert Opin Ther Targets. 2007 Feb;11(2):133-44 [17227230.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):268-74 [17270016.001]
  • [Cites] Appl Environ Microbiol. 2007 Feb;73(4):1146-52 [17158611.001]
  • [Cites] Appl Environ Microbiol. 2007 May;73(10):3272-82 [17400789.001]
  • [Cites] Nat Prod Rep. 2008 Feb;25(1):35-94 [18250897.001]
  • [ErratumIn] J Nat Prod. 2010 Apr 23;73(4):796
  • (PMID = 19117399.001).
  • [ISSN] 1520-6025
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA048112; United States / NCI NIH HHS / CA / R37 CA044848; United States / NCI NIH HHS / CA / CA048112-150007; United States / NCI NIH HHS / CA / P01 CA048112-150007; United States / NCI NIH HHS / CA / R37 CA044848-22; United States / NCI NIH HHS / CA / P01 CA48112; United States / NCI NIH HHS / CA / CA044848-22; United States / FIC NIH HHS / TW / U01 TW007401; United States / FIC NIH HHS / TW / U01-TW007401-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Depsipeptides; 0 / Lipopolysaccharides; 0 / NF-kappa B; 0 / Tumor Necrosis Factor-alpha; 0 / arenamide A; 0 / arenamide B; 0 / arenamide C; 31C4KY9ESH / Nitric Oxide; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ NIHMS91488; NLM/ PMC2837138
  •  go-up   go-down


30. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML: High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients. J Gastrointest Surg; 2007 Nov;11(11):1410-5; discussion 1415-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients.
  • Anal dysplasia (low-grade squamous intraepithelial lesions, LSIL; high-grade squamous intraepithelial lesions, HSIL) is a challenging disease for the surgeon.
  • We reviewed 42 patients that underwent high-resolution anoscopy (HRA)-targeted surgical therapy of anal dysplasia in the past 10 years.
  • Patients were followed up in the Anal Neoplasia Clinic with physical examination, cytology, HRA, and biopsy if indicated.
  • Progression to HSIL was seen in one patient with LSIL and to squamous cell carcinoma in one patient with HSIL despite therapy.
  • HRA-targeted surgical therapy coupled with surveillance and re-treatment with office-based therapies offered an effective method in controlling anal dysplasia in the immunocompetent patient.
  • Morbidity is minimal, and our progression to cancer rate is low (2.4%).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / surgery

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):36-40 [16283561.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):782-5 [3652891.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):126 [16222485.001]
  • [Cites] Arch Surg. 2004 Mar;139(3):259-61 [15006881.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):690-8 [11357031.001]
  • [Cites] Br J Surg. 1999 Aug;86(8):1063-6 [10460644.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):355-73 [15137962.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):912-8 [9269807.001]
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):919-28 [9269808.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1133-6 [16044425.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • (PMID = 17710507.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Das DK, Sharma PN: Intranuclear cytoplasmic inclusions and nuclear grooves in fine needle aspiration smears of papillary thyroid carcinoma and its variants: advantage of the count under an oil-immersion objective over a high-power objective. Anal Quant Cytol Histol; 2005 Apr;27(2):83-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intranuclear cytoplasmic inclusions and nuclear grooves in fine needle aspiration smears of papillary thyroid carcinoma and its variants: advantage of the count under an oil-immersion objective over a high-power objective.
  • OBJECTIVE: To determine the advantage of examining fine needle aspiration (FNA) smears of papillary thyroid carcinoma (PTC) under a 100 x oil-immersion objective, which is capable of optically sectioning the cells.
  • STUDY DESIGN: Two hundred neoplastic cells were counted under a high-power (40x) objective as well as oil-immersion (100x) objective in 54 PTC cases classified into variants: 14 follicular neoplasms, 8 Hürthle cell neoplasms, 5 medullary thyroid carcinomas and 9 hyperplastic lesions.
  • In PTC cases, the mean cell count, 10.1 (+/- 1.75 SE) with INCIs, under the oil-immersion objective was significantly higher than the count, 6.1 (+/- 1.32 SE), under the high-power objective (p = 0.023).
  • In PTC the mean cell count, 88.0 (+/- 4.96 SE), with grooved nuclei under the oil-immersion objective was also significantly higher than the count, 69.5 (+/- 4.87 SE), under the high-power objective (p = 0.010).
  • In PTC the mean cell counts with INCIs as well as grooved nuclei under the oil-immersion objective were significantly higher than those of follicular neoplasms, Hürthle cell neoplasms, medullary carcinoma and hyperplastic lesions.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913201.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oils
  •  go-up   go-down


32. Salit IE, Tinmouth J, Chong S, Raboud J, Diong C, Su D, Sano M, Lytwyn A, Chapman W, Mahony J: Screening for HIV-associated anal cancer: correlation of HPV genotypes, p16, and E6 transcripts with anal pathology. Cancer Epidemiol Biomarkers Prev; 2009 Jul;18(7):1986-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for HIV-associated anal cancer: correlation of HPV genotypes, p16, and E6 transcripts with anal pathology.
  • BACKGROUND: HIV-positive men with a history of anal-receptive intercourse are at risk for anal cancer.
  • We determined whether human papilloma virus (HPV) biomarkers were correlated with anal pathology in these men.
  • The number of HPV genotypes per anal swab was higher for anal intraepithelial neoplasia (AIN) 2/3 than for normal or AIN 1 histology [median, 5 types (interquartile range) (IQR), 3-7 versus 3.5 (IQR), 2-6; P = 0.0005].
  • CONCLUSIONS: The presence of high-grade anal pathology (AIN 2/3) in HIV-positive men was associated with multiple HPV genotypes, HPV genotypes 16 and 31, and HPV 16 viral load.
  • [MeSH-major] Alphapapillomavirus / genetics. Anus Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Genes, p16. HIV Seropositivity / virology. Oncogene Proteins, Viral / genetics. Repressor Proteins / genetics

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19567510.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Repressor Proteins
  •  go-up   go-down


33. Kuramitsu Y: Can proteomics lead to the discovery of real biomarkers for HCC? World J Hepatol; 2010 Feb 27;2(2):55-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of proteomics technologies has lead to a great deal of effort being focused on the identification of biomarkers for cancers.
  • Although many papers have reported candidate biomarkers for hepatocellular carcinomas (HCCs) in particular, so far none of these candidate biomarkers have been used either for diagnosis or therapy intreating patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160973.001).
  • [ISSN] 1948-5182
  • [Journal-full-title] World journal of hepatology
  • [ISO-abbreviation] World J Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999271
  • [Keywords] NOTNLM ; Biomarker / Hepatocellular carcinoma / Mass spectrometry / Proteomics / Two-dimensional polyacrylamide gel electrophoresis
  •  go-up   go-down


34. Dhanarasu S, Selvam M, Salama SM, Shanmugam M, Sethuraman P: Terminalia Arjuna (Roxb.) Modulates Circulatory Antioxidants on 7,12-dimethylbenz(a)anthracene- induced Hamster Buccal Pouch Carcinogenesis. Oman Med J; 2010 Oct;25(4):276-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Oral cancer is the fifth most frequent cancer worldwide and India has recorded the highest incidence (40-50%) of oral malignancy.
  • METHODS: Male Syrian golden hamsters painted with 0.5% 7,12-dimethylbenz[a]anthracene on the buccal pouches and developed oral squamous cell carcinoma were included in this study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22043357.001).
  • [ISSN] 2070-5204
  • [Journal-full-title] Oman medical journal
  • [ISO-abbreviation] Oman Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Oman
  • [Other-IDs] NLM/ PMC3191666
  •  go-up   go-down


35. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Muñoz N, Schiffman M, Bosch FX: Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine; 2008 Aug 19;26 Suppl 10:K17-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions.
  • The association of HPV DNA with several different ano-genital cancers other than cervical has been reported for the vulva, vagina, anus and penis.
  • HPV DNA has also been identified in head and neck cancers in the oral cavity, the oropharynx and the larynx in both sexes.
  • In men, 80-85% of anal cancers and close to 50% of penile cancers are associated with HPV infection.
  • In women, HPV DNA is prevalent in 36-40% vulvar cancer cases and close to 90% of vaginal cancers.
  • Among HPV DNA positive ano-genital cancer cases, HPV-16 is the most frequently found followed distantly by HPV-18.
  • We summarize the evidence linking HPV in the epidemiology and etiology of cancers of the vulva, vagina, anus and oropharynx and present recent estimates of the burden of and HPV type distribution in genital warts and in cases of HPV infection of the airways.
  • [MeSH-minor] Anus Neoplasms / virology. Female. Humans. Male. Papillomaviridae / immunology. Papillomaviridae / pathogenicity. Respiratory Tract Infections / epidemiology. Respiratory Tract Infections / virology. Uterine Cervical Diseases / epidemiology. Uterine Cervical Diseases / virology

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18847554.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098803
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 91
  • [Other-IDs] NLM/ NIHMS73638; NLM/ PMC4366004
  •  go-up   go-down


36. Okoń K, Sińczak-Kuta A, Stachura J: Renal papillary carcinoma classification into subtypes may be reproduced by nuclear morphometry. Anal Quant Cytol Histol; 2009 Apr;31(2):109-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal papillary carcinoma classification into subtypes may be reproduced by nuclear morphometry.
  • OBJECTIVE: To analyze relationships between nuclear features of papillary renal cell carcinoma (PapRCC) subtypes.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19402388.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB: Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One; 2009;4(5):e5583
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.
  • Malignant ascites fluid is rich in LPA, and LPA receptors are aberrantly expressed by ovarian cancer cells, implicating LPA in the initiation and progression of ovarian cancer.
  • However, there is an absence of systematic data critically analyzing the transcriptional changes induced by LPA in ovarian cancer.
  • METHODOLOGY AND PRINCIPAL FINDINGS: In this study, gene expression profiling was used to examine LPA-mediated transcription by exogenously adding LPA to human epithelial ovarian cancer cells for 24 h to mimic long-term stimulation in the tumor microenvironment.
  • The resultant transcriptional profile comprised a 39-gene signature that closely correlated to serous epithelial ovarian carcinoma.
  • Hierarchical clustering of ovarian cancer patient specimens demonstrated that the signature is associated with worsened prognosis.
  • They have a higher frequency of stage IIIc serous carcinoma and a greater proportion is deceased.
  • Among the 39-gene signature, a group of seven genes associated with cell adhesion recapitulated the results.
  • Out of those seven, claudin-1, an adhesion molecule and phenotypic epithelial marker, is the only independent biomarker of serous epithelial ovarian carcinoma.
  • Knockdown of claudin-1 expression in ovarian cancer cells reduces LPA-mediated cellular adhesion, enhances suspended cells and reduces LPA-mediated migration.
  • CONCLUSIONS: The data suggest that transcriptional events mediated by LPA in the tumor microenvironment influence tumor progression through modulation of cell adhesion molecules like claudin-1 and, for the first time, report an LPA-mediated expression signature in ovarian cancer that predicts a worse prognosis.
  • [MeSH-minor] Blotting, Western. Cell Adhesion / genetics. Cell Adhesion / physiology. Cell Line, Tumor. Cell Proliferation. Cell Survival / genetics. Cell Survival / physiology. Claudin-1. Cluster Analysis. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Membrane Proteins / genetics. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3704-10 [10589790.001]
  • [Cites] Mol Oncol. 2008 Jun;2(1):54-69 [19081821.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):291-300 [11330965.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):520-5 [11395428.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64 [12069836.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1073-82 [12615725.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):582-91 [12894246.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Aug;17(4):909-25, vii [12959182.001]
  • [Cites] Genome Biol. 2003;4(10):R70 [14519205.001]
  • [Cites] Nucleic Acids Res. 2003 Dec 15;31(24):e154 [14654707.001]
  • [Cites] Endocrinology. 2004 Jun;145(6):2929-40 [14988385.001]
  • [Cites] J Cell Biochem. 2004 Aug 15;92(6):1115-40 [15258897.001]
  • [Cites] Arterioscler Thromb. 1993 Nov;13(11):1662-7 [8218108.001]
  • [Cites] Biochem J. 1998 Mar 15;330 ( Pt 3):1107-14 [9494074.001]
  • [Cites] Ann Oncol. 1998 Apr;9(4):437-42 [9636836.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):364-8 [9887232.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6249-54 [10339573.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):355-66 [15864277.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4672-87 [15940270.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1765-76 [15965503.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9603-6 [16266975.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10602-12 [16288054.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1354-62 [16452189.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2740-8 [16510595.001]
  • [Cites] Matrix Biol. 2006 May;25(4):223-31 [16503403.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22786-93 [16782709.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(16):2846-54 [16996261.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):591-8 [16797678.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Am J Obstet Gynecol. 2007 Mar;196(3):245.e1-11 [17346539.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):928-37 [17509990.001]
  • [Cites] Expert Rev Mol Med. 2007;9(28):1-18 [17935635.001]
  • [Cites] Hum Pathol. 2008 May;39(5):747-57 [18439941.001]
  • [Cites] Adv Exp Med Biol. 2008;617:23-40 [18497028.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5198-208 [18698038.001]
  • [Cites] Biochim Biophys Acta. 2008 Sep;1781(9):547-57 [18501205.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]
  • (PMID = 19440550.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA099031; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Lysophospholipids; 0 / Membrane Proteins; 22002-87-5 / lysophosphatidic acid
  • [Other-IDs] NLM/ PMC2679144
  •  go-up   go-down


38. Choi AO, Brown SE, Szyf M, Maysinger D: Quantum dot-induced epigenetic and genotoxic changes in human breast cancer cells. J Mol Med (Berl); 2008 Mar;86(3):291-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantum dot-induced epigenetic and genotoxic changes in human breast cancer cells.
  • We examined here the epigenomic and genotoxic response to cadmium telluride quantum dots (QDs) in human breast carcinoma cells.
  • Consequential decrease in cell viability was in part prevented by the p53 inhibitor pifithrin-alpha, suggesting that p53 translocation contributes to QD-induced cytotoxicity.
  • [MeSH-minor] Acetylation. Animals. Apoptosis Regulatory Proteins / genetics. Apoptosis Regulatory Proteins / metabolism. Cell Line, Tumor. Cell Nucleus / metabolism. Cell Nucleus / ultrastructure. Chromatin / metabolism. Chromatin / ultrastructure. Gene Expression Regulation, Neoplastic. Histones / metabolism. Humans. Mitochondria / ultrastructure. Models, Biological. PC12 Cells. Phosphorylation. Protein Processing, Post-Translational. Protein Transport. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2006 Jun;27(6):1121-5 [16699174.001]
  • [Cites] Eur J Pharm Biopharm. 2007 Mar;65(3):270-81 [17027243.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1199-205 [17110788.001]
  • [Cites] FEBS Lett. 2007 Jul 31;581(19):3743-8 [17433304.001]
  • [Cites] J Invest Dermatol. 2007 Jan;127(1):143-53 [16902417.001]
  • [Cites] Cell Death Differ. 2005 Nov;12 Suppl 2:1528-34 [16247500.001]
  • [Cites] Biomaterials. 2006 Mar;27(9):1679-87 [16318871.001]
  • [Cites] Environ Health Perspect. 2006 Feb;114(2):165-72 [16451849.001]
  • [Cites] Free Radic Biol Med. 2004 Sep 1;37(5):582-93 [15288116.001]
  • [Cites] J Nanobiotechnology. 2006 Oct 20;4:10 [17054792.001]
  • [Cites] J Mol Med (Berl). 2005 May;83(5):377-85 [15688234.001]
  • [Cites] Science. 2006 Feb 3;311(5761):622-7 [16456071.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13540-7 [16531610.001]
  • [Cites] Int J Mol Med. 1998 Jun;1(6):1001-6 [9852638.001]
  • [Cites] Nature. 2000 Jan 6;403(6765):41-5 [10638745.001]
  • [Cites] J Nanobiotechnology. 2007 Feb 12;5:1 [17295922.001]
  • [Cites] J Neurooncol. 2000;46(2):125-33 [10894365.001]
  • [Cites] Nat Cell Biol. 2003 Apr;5(4):320-9 [12652308.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4697-705 [16892083.001]
  • [Cites] Langmuir. 2007 Feb 13;23 (4):1974-80 [17279683.001]
  • [Cites] Chem Commun (Camb). 2005 Jan 7;(1):121-3 [15614393.001]
  • [Cites] Hum Mol Genet. 2006 Apr 15;15 Spec No 1:R95-101 [16651376.001]
  • [Cites] EMBO J. 2006 Oct 18;25(20):4952-62 [17024184.001]
  • [Cites] Nat Biotechnol. 2004 Nov;22(11):1360-1 [15529155.001]
  • [Cites] Anal Bioanal Chem. 2006 Oct;386(3):444-57 [16850295.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):857-66 [16327764.001]
  • [Cites] Mol Cell. 1998 Oct;2(4):405-15 [9809062.001]
  • [Cites] Cell Cycle. 2004 Jul;3(7):836-9 [15190209.001]
  • [Cites] DNA Cell Biol. 2006 Feb;25(2):124-34 [16460236.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):761-77 [15865932.001]
  • [Cites] Biomed Pharmacother. 2005 May;59(4):139-42 [15862706.001]
  • [Cites] Chem Biol. 2005 Nov;12 (11):1227-34 [16298302.001]
  • [Cites] Nano Lett. 2006 Jul;6(7):1491-5 [16834436.001]
  • [Cites] Nat Chem Biol. 2006 Sep;2(9):474-9 [16862141.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2797-808 [15077143.001]
  • (PMID = 17965848.001).
  • [ISSN] 0946-2716
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Chromatin; 0 / Histones; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


39. Bravo SB, Garcia-Rendueles ME, Perez-Romero S, Cameselle-Teijeiro J, Rodrigues JS, Barreiro F, Alvarez CV: Expression of exogenous proteins and short hairpin RNAs in human primary thyrocytes. Anal Biochem; 2010 May 15;400(2):219-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, it has been shown that commercial human thyroid lines were in fact derived from colon, mammary carcinoma, or melanoma.
  • Others have demonstrated the absence of a common pattern of gene expression between available thyroid cancer cell lines and tumors from patients.
  • Nucleofection was unquestionably the most efficient even for promoter regulation studies, and it was effective in cultures from different origins as normal thyroid, papillary carcinoma, or lymphoid node metastasis.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20122891.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins; 63231-63-0 / RNA
  •  go-up   go-down


40. Williams SJ, Cvetkovic D, Hamilton TC: Vitamin A metabolism is impaired in human ovarian cancer. Gynecol Oncol; 2009 Mar;112(3):637-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin A metabolism is impaired in human ovarian cancer.
  • METHODS: We assessed CRBP1 expression by immunohistochemistry in ovaries prophylactically removed from women with a genetic risk for ovarian cancer.
  • HPLC analysis of vitamin A metabolism showed production of retinoic acid in four independent, normal human ovarian surface epithelial (HOSE) cell cultures upon exposure to retinol.
  • However, only one of two SV40-immortalized HOSE cell lines made RA, while none of the ovarian carcinoma cell lines produced detectable RA due to complete loss of RALDH2.
  • CONCLUSIONS: The impaired conversion of retinol to RA in ovarian cancer cells and decreased CRBP1 protein expression in prophylactic oophorectomies support our hypothesis that concomitant losses of vitamin A metabolism and CRBP1 expression contribute to ovarian oncogenesis.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin A.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. VITAMIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2002 Mar;72(2):95-105 [12038710.001]
  • [Cites] J Natl Cancer Inst. 1992 Apr 15;84(8):592-601 [1556770.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45408-19 [12237293.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):485-95 [12498717.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1013-20 [12631600.001]
  • [Cites] Hepatology. 2003 Aug;38(2):470-80 [12883492.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2599-606 [14669279.001]
  • [Cites] J Clin Pathol. 2004 Aug;57(8):872-6 [15280411.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7065-70 [11585737.001]
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):128-34 [11668487.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1283-9 [11688463.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2318-26 [11745286.001]
  • [Cites] Oncogene. 2001 Nov 29;20(55):7935-44 [11753676.001]
  • [Cites] DNA Cell Biol. 2002 Jan;21(1):11-9 [11879576.001]
  • [Cites] Leukemia. 2002 Apr;16(4):463-72 [11960323.001]
  • [Cites] Am J Obstet Gynecol. 1992 Sep;167(3):729-35 [1326894.001]
  • [Cites] Int J Gynecol Pathol. 1993 Jan;12(1):59-63 [8418079.001]
  • [Cites] Comp Biochem Physiol Comp Physiol. 1993 Dec;106(4):749-54 [7906633.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2778-84 [8168110.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):146-7 [7707390.001]
  • [Cites] Am J Obstet Gynecol. 1995 Aug;173(2):558-65 [7645635.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jun;81(6):2186-91 [8964849.001]
  • [Cites] FASEB J. 1996 Jul;10(9):1031-9 [8801164.001]
  • [Cites] FASEB J. 1996 Jul;10(9):1064-70 [8801168.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1810-20 [8961970.001]
  • [Cites] Exp Cell Res. 1997 Nov 25;237(1):118-26 [9417874.001]
  • [Cites] Methods Mol Biol. 1998;89:57-66 [9664318.001]
  • [Cites] J Chromatogr A. 1998 Dec 18;828(1-2):451-60 [9916324.001]
  • [Cites] Biotechniques. 1999 Feb;26(2):282-3, 286-9 [10023540.001]
  • [Cites] Int J Gynecol Pathol. 1999 Apr;18(2):151-7 [10202673.001]
  • [Cites] Gynecol Oncol. 1999 May;73(2):229-36 [10329039.001]
  • [Cites] Biochim Biophys Acta. 1999 Sep 22;1440(2-3):139-62 [10521699.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 5;97(1):3-4 [15632368.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):67-74 [15720818.001]
  • [Cites] Int J Cancer. 2005 Jul 10;115(5):747-51 [15704093.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1477-87 [16012182.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8118-24 [16166285.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10308-14 [17079450.001]
  • [Cites] Cancer. 1999 Oct 15;86(8):1544-50 [10526284.001]
  • [Cites] J Natl Cancer Inst. 1999 Nov 3;91(21):1847-56 [10547391.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 15;92(6):475-80 [10716965.001]
  • [Cites] Carcinogenesis. 2000 Jul;21(7):1271-9 [10874003.001]
  • [Cites] Physiol Rev. 2000 Jul;80(3):1021-54 [10893430.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2728-32 [10894872.001]
  • [Cites] J Cell Physiol. 2000 Oct;185(1):1-20 [10942515.001]
  • [Cites] Nutr Rev. 2000 Aug;58(8):230-6 [10946560.001]
  • [Cites] J Cell Physiol. 2000 Nov;185(2):302-9 [11025452.001]
  • [Cites] J Cell Physiol. 2001 Mar;186(3):437-47 [11169983.001]
  • [Cites] Cancer Causes Control. 2001 Jan;12(1):83-90 [11227928.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2774-81 [11289161.001]
  • [Cites] Br J Cancer. 2001 Jul 6;85(1):122-8 [11437413.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5895-904 [11479231.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5379-89 [6604576.001]
  • [Cites] Biochem Med Metab Biol. 1987 Apr;37(2):213-9 [3593592.001]
  • [Cites] Arch Gynecol Obstet. 1987;241(3):151-6 [3435184.001]
  • [Cites] Methods Enzymol. 1990;189:315-24 [1963464.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):851-8 [12153175.001]
  • (PMID = 19110304.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA107195; United States / NCI NIH HHS / CA / R01 CA107195-01A2; United States / NCI NIH HHS / CA / CA107195-01A2; United States / NCI NIH HHS / CA / P50 CA083638-040001; United States / NCI NIH HHS / CA / CA107195-03; United States / NCI NIH HHS / CA / CA107195-02; United States / NCI NIH HHS / CA / P50 CA083638-030001; United States / NCI NIH HHS / CA / CA083638-030001; United States / NCI NIH HHS / CA / R01 CA107195-03; United States / NCI NIH HHS / CA / CA 83638; United States / NCI NIH HHS / CA / R01 CA107195-04; United States / NCI NIH HHS / CA / R01 CA107195-02; United States / NCI NIH HHS / CA / CA107195-04; United States / NCI NIH HHS / CA / P50 CA083638; United States / NCI NIH HHS / CA / CA083638-040001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retinol-Binding Proteins, Cellular; 11103-57-4 / Vitamin A; 5688UTC01R / Tretinoin; RR725D715M / Retinaldehyde
  • [Other-IDs] NLM/ NIHMS102172; NLM/ PMC2737361
  •  go-up   go-down


41. Alvarez J, de Pokomandy A, Rouleau D, Ghattas G, Vézina S, Coté P, Allaire G, Hadjeres R, Franco EL, Coutlée F, HIPVIRG Study Group: Episomal and integrated human papillomavirus type 16 loads and anal intraepithelial neoplasia in HIV-seropositive men. AIDS; 2010 Sep 24;24(15):2355-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Episomal and integrated human papillomavirus type 16 loads and anal intraepithelial neoplasia in HIV-seropositive men.
  • OBJECTIVES: To assess levels of episomal and integrated human papillomavirus type 16 (HPV-16) loads in HIV-seropositive men who have sex with men (MSM) in anal infection and to study the association between episomal and integrated HPV-16 loads and anal intraepithelial neoplasia (AIN).
  • Overall, 135 (54.7%) men provided 665 HPV-16-positive anal samples.
  • RESULTS: The HPV-16 DNA forms in anal samples were characterized as episomal only in 627 samples (94.3%), mixed in 22 samples (3.3%) and integrated only in nine samples (1.4%).
  • HPV-16 episomal load [odds ratio (OR) = 1.5, 95% confidence interval (CI) 1.1-2.1], number of HPV types (OR = 1.4, 95% CI 1.1-1.8) and current smoking (OR = 4.8, 95% CI 1.3-18.6) were associated with high-grade AIN (AIN-2,3) after adjusting for age and CD4 cell counts.
  • [MeSH-major] Anus Neoplasms / immunology. Carcinoma, Squamous Cell / immunology. HIV Seropositivity / immunology. Human papillomavirus 16 / immunology. Papillomavirus Infections / immunology. Plasmids / immunology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20706109.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Investigator] Allaire G; Baril JG; Boissonnault M; Charest L; Charron MA; Coté S; Coté P; Coutlée F; de Pokomandy A; Dion H; Dufresne S; Falutz J; Fortin C; Franco EL; Ghattas G; Gilmore N; Gorska I; Hadjeres R; Junod P; Klein M; Lalonde R; Laplante F; Leblanc R; Legault D; Lessard B; Longpré D; McLeod J; Maziade JP; Murphy D; Nguyen VK; O'Brien R; Phaneuf D; Rouleau D; Routy JP; Szabo J; Tessier D; Thomas R; Toma E; Tremblay C; Trépanier JM; Trottier B; Tsoukas C; Turner H; Vezina S
  •  go-up   go-down


42. Dharmu I, Ramamurty N, Kannan R, Babu M: Cytotoxic effect of achatinin(H) (lectin) from Achatina fulica against a human mammary carcinoma cell line (MCF7). In Vitro Cell Dev Biol Anim; 2007 Sep-Oct;43(8-9):306-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic effect of achatinin(H) (lectin) from Achatina fulica against a human mammary carcinoma cell line (MCF7).
  • The hemolymph-derived achatinin(H) (lectin) from Achatina fulica showed a marked cytotoxic effect on MCF7, a human mammary carcinoma cell line.
  • MCF7 cells showed significant morphological changes leading to cell death.
  • The above cell death was observed after 48 h of treatment with 8 microg/ml when compared to untreated cells.
  • Fluorescence-activated cell sorting analysis of the cell cycle showed a significant increase in S-phase in MCF7 cells after 48 h of achatinin(H) treatment.
  • The cells were arrested in G(2)/M phase of the cell cycle after 48 h with significant changes in cell viability.
  • [MeSH-minor] Animals. Antioxidants / metabolism. Biomarkers, Tumor / metabolism. Blotting, Western. Cell Count. Cell Cycle / drug effects. Cell Death / drug effects. Cell Line, Tumor. Cell Survival / drug effects. DNA, Neoplasm / isolation & purification. Electrophoresis, Agar Gel. Female. Flow Cytometry. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] In Vitro Cell Dev Biol Anim. 2007 Nov-Dec;43(10):379-81
  • [Cites] Mol Cell Biochem. 1986 Aug;71(2):149-57 [2430170.001]
  • [Cites] Acta Oncol. 1990;29(2):151-4 [2159313.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] J Invertebr Pathol. 1982 Mar;39(2):210-4 [7086162.001]
  • [Cites] Comp Biochem Physiol B Biochem Mol Biol. 1997 Aug;117(4):545-52 [9297799.001]
  • [Cites] J Histochem Cytochem. 1995 Mar;43(3):275-81 [7868857.001]
  • [Cites] J Exp Med. 1979 Jan 1;149(1):273-8 [310861.001]
  • [Cites] EMBO J. 1991 Jul;10(7):1661-9 [2050106.001]
  • [Cites] Blood. 1990 Dec 1;76(11):2327-36 [2257305.001]
  • [Cites] Pathol Res Pract. 1992 Apr;188(3):284-6 [1625991.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Nov 12;228(2):467-73 [8920936.001]
  • [Cites] J Pathol. 1987 Jul;152(3):169-76 [3309230.001]
  • [Cites] Science. 1973 Feb 9;179(4073):588-90 [4686466.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):279-85 [3663476.001]
  • [Cites] Theriogenology. 2003 Mar;59(5-6):1277-89 [12527075.001]
  • [Cites] Tumour Biol. 2000 Jan-Feb;21(1):3-10 [10601836.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Int J Cancer. 1979 Oct 15;24(4):471-6 [528070.001]
  • [Cites] J Pharmacol Toxicol Methods. 1995 Feb;33(1):1-10 [7727802.001]
  • [Cites] J Immunol Methods. 1994 Sep 14;174(1-2):311-20 [8083535.001]
  • [Cites] FEBS Lett. 1993 Dec 20;336(1):137-42 [8262197.001]
  • [Cites] Eur J Biochem. 1994 May 1;221(3):979-86 [8181481.001]
  • [Cites] Cancer Lett. 1999 Sep 20;144(1):31-7 [10503875.001]
  • [Cites] J Biol Chem. 1984 Jun 25;259(12):7453-9 [6203895.001]
  • [Cites] J Cell Physiol. 1990 May;143(2):251-6 [2159014.001]
  • [Cites] Cytometry. 1997 Jan 1;27(1):1-20 [9000580.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Science. 1989 Oct 13;246(4927):227-34 [2552581.001]
  • [Cites] Br J Cancer. 1993 Sep;68(3):621-6 [8102537.001]
  • [Cites] Eur J Biochem. 1974 Sep 16;47(3):469-74 [4215654.001]
  • [Cites] Int J Radiat Biol. 1998 May;73(5):455-67 [9652802.001]
  • [Cites] Cancer Res. 1995 Dec 15;55(24):6021-5 [8521385.001]
  • [Cites] Anal Biochem. 1972 Jun;47(2):389-94 [4556490.001]
  • [Cites] Mol Biol Rep. 2005 Sep;32(3):191-6 [16172920.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Biull Eksp Biol Med. 1985 Jul;100(7):51-3 [3860263.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2000 Sep;127(2):177-83 [11083028.001]
  • [Cites] J Cell Comp Physiol. 1946 Oct;28(2):197-208 [21002966.001]
  • [Cites] Indian J Biochem Biophys. 1997 Feb-Apr;34(1-2):82-6 [9343933.001]
  • (PMID = 17876678.001).
  • [ISSN] 1071-2690
  • [Journal-full-title] In vitro cellular & developmental biology. Animal
  • [ISO-abbreviation] In Vitro Cell. Dev. Biol. Anim.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Lectins; 0 / achatinin(H)
  •  go-up   go-down


43. Aalen OO, Gunnes N: A dynamic approach for reconstructing missing longitudinal data using the linear increments model. Biostatistics; 2010 Jul;11(3):453-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Analysis of quality of life data from a cancer clinical trial is analyzed and presented.
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Clinical Trials, Phase III as Topic. Computer Simulation. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Patient Dropouts. Quality of Life

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Epidemiology. 2000 Sep;11(5):561-70 [10955409.001]
  • [Cites] Eur J Cancer. 2002 Mar;38 Suppl 4:S125-33 [11858978.001]
  • [Cites] Stat Med. 2009 Jan 30;28(2):221-39 [19012297.001]
  • [Cites] Stat Med. 2009 Feb 15;28(4):605-24 [19035531.001]
  • [Cites] BMC Med Res Methodol. 2009;9:28 [19405936.001]
  • [Cites] Lifetime Data Anal. 2010 Jan;16(1):118-35 [19701791.001]
  • [Cites] Lifetime Data Anal. 2006 Jun;12(2):143-67 [16817006.001]
  • [Cites] Stat Med. 2003 Aug 15;22(15):2429-41 [12872300.001]
  • [Cites] Stat Med. 2004 May 15;23(9):1455-97 [15116353.001]
  • [Cites] Stat Med. 2004 Jul 30;23(14):2215-26 [15236426.001]
  • [Cites] Stat Methods Med Res. 1999 Mar;8(1):3-15 [10347857.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):237-42 [16611197.001]
  • [Cites] Stat Med. 2010 Nov 20;29(26):2757-68 [20803557.001]
  • (PMID = 20388914.001).
  • [ISSN] 1468-4357
  • [Journal-full-title] Biostatistics (Oxford, England)
  • [ISO-abbreviation] Biostatistics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3293429
  •  go-up   go-down


44. Janani P, Sivakumari K, Geetha A, Ravisankar B, Parthasarathy C: Chemopreventive effect of bacoside A on N-nitrosodiethylamine-induced hepatocarcinogenesis in rats. J Cancer Res Clin Oncol; 2010 May;136(5):759-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bacoside A, the active constituent of Bacopa monniera Linn., is anticipated to play a role in chemoprevention of liver cancer.
  • Bacoside A co-treatment maintained the N-nitrosodiethylamine-induced alterations at near normal level.
  • CONCLUSIONS: From our findings we conclude that bacoside A is effective to prevent DEN-induced hepatocellular carcinoma by quenching lipid peroxidation and enhancing antioxidant status through free radical scavenging mechanism and having potential of protecting endogenous enzymatic and non-enzymatic antioxidant activity.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Carcinoma, Hepatocellular / prevention & control. Diethylnitrosamine / antagonists & inhibitors. Liver Neoplasms, Experimental / prevention & control. Saponins / pharmacology. Triterpenes / pharmacology

  • Hazardous Substances Data Bank. N-NITROSODIETHYLAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Phytother Res. 2002 Mar;16(2):197-8 [11933129.001]
  • [Cites] Cancer. 1962 Mar-Apr;15:347-53 [13909713.001]
  • [Cites] Biosci Biotechnol Biochem. 1998 Dec;62(12):2291-9 [9972256.001]
  • [Cites] Int J Cancer. 1997;Suppl 10:18-21 [9209015.001]
  • [Cites] J Biol Chem. 2003 Aug 15;278(33):31426-33 [12775726.001]
  • [Cites] Cancer. 1965 Jul;18:886-92 [14308236.001]
  • [Cites] Phytochemistry. 1995 Jan;38(1):229-31 [7766056.001]
  • [Cites] Phytomedicine. 2001 Nov;8(6):423-30 [11824516.001]
  • [Cites] Histopathology. 2001 Feb;38(2):167-74 [11207830.001]
  • [Cites] J Biol Chem. 1988 Aug 15;263(23):11436-42 [2457023.001]
  • [Cites] Phytother Res. 2001 Nov;15(7):643-5 [11746853.001]
  • [Cites] Toxicol Pathol. 1989;17(4 Pt 1):594-611; discussion 611-2 [2697939.001]
  • [Cites] Clin Biochem. 1998 Jun;31(4):269-72 [9646951.001]
  • [Cites] Indian J Exp Biol. 2004 Aug;42(8):776-80 [15573526.001]
  • [Cites] J Natl Cancer Inst. 1978 Jan;60(1):19-26 [75267.001]
  • [Cites] Biochim Biophys Acta. 1969 Jul 8;185(1):39-48 [5796111.001]
  • [Cites] Cell Mol Biol Lett. 2003;8(2):391-413 [12813574.001]
  • [Cites] Indian J Physiol Pharmacol. 1995 Jul;39(3):177-96 [8550109.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):537-43 [12094240.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):688-94 [9024706.001]
  • [Cites] Phytomedicine. 2005 Apr;12(4):305-17 [15898709.001]
  • [Cites] Cell Biochem Funct. 2001 Dec;19(4):265-71 [11746207.001]
  • [Cites] J Biol Chem. 1969 Nov 25;244(22):6056-63 [4981789.001]
  • [Cites] Science. 1973 Feb 9;179(4073):588-90 [4686466.001]
  • [Cites] Acta Biochim Pol. 1996;43(2):403-5 [8862187.001]
  • [Cites] Free Radic Biol Med. 1991;11(1):81-128 [1937131.001]
  • [Cites] J Clin Lab Anal. 1991;5(5):344-66 [1941355.001]
  • [Cites] Phytochem Anal. 2005 Jan-Feb;16(1):24-9 [15688952.001]
  • [Cites] Arch Biochem Biophys. 1963 Jan;100:119-30 [14028302.001]
  • [Cites] J Ethnopharmacol. 2003 May;86(1):27-35 [12686438.001]
  • [Cites] J Cancer Res Clin Oncol. 1984;108(2):252-3 [6470034.001]
  • [Cites] J Biol Chem. 1982 May 25;257(10):5751-4 [6279612.001]
  • [Cites] Phytother Res. 2000 May;14(3):174-9 [10815010.001]
  • [Cites] Clin Chem. 1984 Oct;30(10):1607-10 [6148160.001]
  • [Cites] Planta Med. 2001 Nov;67(8):752-4 [11731921.001]
  • [Cites] Clin Chim Acta. 2005 May;355(1-2):173-80 [15820492.001]
  • [Cites] Hepatology. 1990 Apr;11(4):545-50 [1970323.001]
  • [Cites] Cancer Res. 1982 Jun;42(6):2146-58 [6122501.001]
  • [Cites] Arch Biochem Biophys. 1997 Oct 1;346(1):45-52 [9328283.001]
  • [Cites] Phytother Res. 2003 Sep;17(8):870-5 [13680815.001]
  • [Cites] IARC Sci Publ. 1990;(99):199-240 [2093649.001]
  • [Cites] Life Sci. 2003 Aug 8;73(12):1517-26 [12865091.001]
  • [Cites] Biochim Biophys Acta. 1990 Dec 11;1032(2-3):177-89 [2261493.001]
  • [Cites] Biochem Pharmacol. 2002 Jul 15;64(2):207-16 [12123741.001]
  • [Cites] Anal Biochem. 1971 Nov;44(1):276-87 [4943714.001]
  • [Cites] Biochem J. 1982 May 15;204(2):377-81 [6896821.001]
  • [Cites] Cancer. 1985 May 1;55(9):1931-6 [3884132.001]
  • [Cites] J Biol Chem. 1965 Jan;240:338-47 [14253434.001]
  • [Cites] Methods Enzymol. 1984;105:138-47 [6727662.001]
  • [Cites] J Biol Chem. 1972 May 25;247(10):3170-5 [4623845.001]
  • [Cites] Adv Cancer Res. 1971;14:295-358 [4107670.001]
  • [Cites] Chem Phys Lipids. 1987 Nov-Dec;45(2-4):251-68 [3319229.001]
  • [Cites] Arch Toxicol. 2001 Apr;75(2):88-96 [11354911.001]
  • [Cites] Cancer Res. 1976 Nov;36(11 Pt. 2):4239-49 [61804.001]
  • [Cites] World J Gastroenterol. 2004 May 1;10(9):1268-75 [15112340.001]
  • [Cites] J Nat Prod. 2002 Dec;65(12):1759-63 [12502309.001]
  • [Cites] J Vet Sci. 2001 Apr;2(1):53-8 [14614295.001]
  • [Cites] Phytomedicine. 2003;10(6-7):523-7 [13678238.001]
  • [Cites] Cell Biol Toxicol. 2009 Oct;25(5):425-34 [18679812.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Liver. 1990 Jun;10(3):158-66 [2385157.001]
  • [Cites] J Ethnopharmacol. 2006 Mar 8;104(1-2):286-9 [16343831.001]
  • [Cites] Annu Rev Biochem. 1983;52:711-60 [6137189.001]
  • [Cites] Breast Cancer Res Treat. 2000 Jan;59(2):163-70 [10817351.001]
  • [Cites] Cancer. 1980 Jun 15;45(12):2940-8 [7388737.001]
  • [Cites] Biochim Biophys Acta. 1980 May 6;605(2):191-215 [6249365.001]
  • [Cites] Indian J Exp Biol. 1996 Jun;34(6):523-6 [8792640.001]
  • [Cites] Pharmacol Ther. 1996;71(1-2):57-81 [8910949.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Br J Cancer. 1973 Jun;27(6):473-84 [4721221.001]
  • [Cites] Cancer Res. 1978 Mar;38(3):723-8 [626976.001]
  • [Cites] Semin Oncol. 1983 Jun;10 (2):228-37 [6867753.001]
  • [Cites] J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S109-14 [12394214.001]
  • [Cites] Methods Enzymol. 1979;62:3-11 [440112.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):589-95 [10440686.001]
  • [Cites] Br J Cancer. 1978 Jul;38(1):51-4 [80223.001]
  • [Cites] Rev Gastroenterol Disord. 2003 Winter;3(1):8-24 [12684589.001]
  • [Cites] J Ethnopharmacol. 1982 Mar;5(2):205-14 [7057659.001]
  • [Cites] Br Med Bull. 1993 Jul;49(3):679-99 [8221032.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1073-7 [9353183.001]
  • [Cites] Ann N Y Acad Sci. 1987;498:186-99 [3304060.001]
  • [Cites] Am J Clin Nutr. 1976 May;29(5):569-78 [773168.001]
  • [Cites] Physiol Rev. 1994 Jan;74(1):139-62 [8295932.001]
  • (PMID = 19916024.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antioxidants; 0 / Carcinogens; 0 / Plant Extracts; 0 / Saponins; 0 / Triterpenes; 0 / bacoside A; 3IQ78TTX1A / Diethylnitrosamine
  •  go-up   go-down


45. Fox PA: Human papillomavirus and anal intraepithelial neoplasia. Curr Opin Infect Dis; 2006 Feb;19(1):62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus and anal intraepithelial neoplasia.
  • PURPOSE OF REVIEW: A review of recent developments in the understanding of the natural history of anal squamous carcinoma arising from areas of high-grade anal intraepithelial neoplasia.
  • RECENT FINDINGS: Anal intraepithelial neoplasia is a consequence of chronic human papillomavirus infection in the anal canal and appears to be driven by high viral loads of human papillomavirus.
  • Anal intraepithelial neoplasia is equally prevalent in different age groups of men who have sex with men, but in other respects what is known of its natural history resembles that of cervical intraepithelial neoplasia.
  • HIV-positives who practise receptive anal intercourse are at highest risk of anal intraepithelial neoplasia.
  • Screening is easy to perform using cytology; the limitations of anal cytology being similar to those of cervical cytology.
  • [MeSH-major] Anus Neoplasms. Carcinoma in Situ. Carcinoma, Squamous Cell. Papillomaviridae / pathogenicity. Papillomavirus Infections

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374220.001).
  • [ISSN] 0951-7375
  • [Journal-full-title] Current opinion in infectious diseases
  • [ISO-abbreviation] Curr. Opin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


46. Hampl M: Prevention of human papilloma virus-induced preneoplasia and cancer by prophylactic HPV vaccines. Minerva Med; 2007 Apr;98(2):121-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of human papilloma virus-induced preneoplasia and cancer by prophylactic HPV vaccines.
  • Persistent infection with human papilloma virus (HPV) is a necessary condition for the development of cervical, most of the vulvar and anal carcinoma and their precursors.
  • Only persistent infections predispose to the development of genital preneoplasia and cancer.
  • These vaccines constitute a milestone in the battle against cervical carcinoma, which is the second most common cancer in young women in Europe, with 33,500 new cases diagnosed every year.


47. Xu CM, Qiao CH: Loss of fragile histidine triad protein expression in inflammatory bowel disease. World J Gastroenterol; 2006 Dec 7;12(45):7355-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Our results show that FHIT protein expression is completely absent or reduced in IBD, suggesting that the FHIT gene might be associated with the oncogenesis and progression of IBD, an early event from inflammatory conditions to carcinoma in IBD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Immunol. 2001 Jan;22(1):21-6 [11286687.001]
  • [Cites] Cancer Lett. 2006 Jan 28;232(1):37-47 [16242840.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4827-36 [11406559.001]
  • [Cites] BJU Int. 2001 Jun;87(9):876-81 [11412230.001]
  • [Cites] J Clin Pathol. 2001 Jul;54(7):526-32 [11429424.001]
  • [Cites] Mol Med. 2001 Jul;7(7):442-53 [11683369.001]
  • [Cites] Mol Cell Biochem. 2001 Oct;226(1-2):49-55 [11768238.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8668-75 [11751383.001]
  • [Cites] Dig Liver Dis. 2001 Dec;33(9):762-7 [11838611.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Jul;34(3):333-40 [12007194.001]
  • [Cites] Scand J Gastroenterol. 2002 May;37(5):546-54 [12059056.001]
  • [Cites] Carcinogenesis. 2002 Jun;23(6):993-1001 [12082021.001]
  • [Cites] Clin Exp Metastasis. 2002;19(4):351-8 [12090476.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2890-3 [12231533.001]
  • [Cites] Lancet Oncol. 2002 Dec;3(12):748-54 [12473516.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Feb;129(2):84-8 [12669232.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 May;15(5):515-23 [12702909.001]
  • [Cites] Mol Cell Biochem. 2000 Jan;204(1-2):83-8 [10718628.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 27;1470(2):M69-78 [10722929.001]
  • [Cites] Shock. 2000 May;13(5):361-6 [10807010.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):737-45 [10980113.001]
  • [Cites] Gastroenterology. 2000 Oct;119(4):1007-18 [11040187.001]
  • [Cites] J Clin Gastroenterol. 2003 May-Jun;36(5 Suppl):S70-4; discussion S94-6 [12702969.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1501-6 [12771912.001]
  • [Cites] Gastroenterology. 2003 Jun;124(7):1748-57 [12806607.001]
  • [Cites] Transplantation. 2003 Jun 27;75(12):1983-8 [12829898.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Jun;15(6):665-73 [12840679.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):320-6 [12865924.001]
  • [Cites] World J Gastroenterol. 2003 Aug;9(8):1646-56 [12918095.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):2837-43 [12926121.001]
  • [Cites] J Pathol. 2003 Oct;201(2):312-8 [14517849.001]
  • [Cites] World J Gastroenterol. 2003 Nov;9(11):2533-8 [14606091.001]
  • [Cites] Int J Colorectal Dis. 2004 Jul;19(4):325-33 [15060836.001]
  • [Cites] Autoimmun Rev. 2004 Jul;3(5):394-400 [15288007.001]
  • [Cites] Cell. 1996 Feb 23;84(4):587-97 [8598045.001]
  • [Cites] Anal Cell Pathol. 1997;15(2):99-117 [9413595.001]
  • [Cites] Gastroenterology. 1998 Aug;115(2):297-306 [9679035.001]
  • [Cites] Mod Pathol. 1999 Jun;12(6):604-11 [10392637.001]
  • [Cites] World J Gastroenterol. 2005 Jan 7;11(1):17-21 [15609389.001]
  • [Cites] Acta Chir Iugosl. 2004;51(2):109-16 [15771301.001]
  • [Cites] Int J Gastrointest Cancer. 2005;36(1):39-46 [16227634.001]
  • [Cites] Cancer Lett. 2006 Jan 28;232(1):27-36 [16225988.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):143-9 [11396632.001]
  • (PMID = 17143956.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ PMC4087498
  •  go-up   go-down


48. Negri G, Moretto G, Menia E, Vittadello F, Kasal A, Mian C, Egarter-Vigl E: Immunocytochemistry of p16INK4a in liquid-based cervicovaginal specimens with modified Papanicolaou counterstaining. J Clin Pathol; 2006 Aug;59(8):827-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Immunocytochemical analyses were carried out with p16(INK4a) and modified Papanicolaou counterstain on 81 liquid-based samples, including 23 of within normal limits (WNL), 6 of low-grade squamous intraepithelial lesion (LSIL), 20 of high-grade squamous intraepithelial lesion (HSIL), 16 of atypical squamous cells of undetermined significance (ASC-US) and 16 of atypical squamous cells, high-grade lesion cannot be excluded (ASC-H).
  • The intensity of immunostaining in cases of squamous intraepithelial lesion (SIL) was assessed using a 0-3 scoring system.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Squamous Cell / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Diagnosis, Differential. Feasibility Studies. Female. Humans. Neoplasm Proteins / analysis. Papanicolaou Test. Staining and Labeling / methods. Uterine Cervical Dysplasia / diagnosis. Vaginal Smears / methods

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2003 Jul;16(7):665-73 [12861062.001]
  • [Cites] Acta Cytol. 2003 Jul-Aug;47(4):616-23 [12920756.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):187-93 [12548164.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):56-63 [12499437.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):689-96 [15188135.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):201-8 [14529682.001]
  • [Cites] Cancer. 2004 Apr 25;102(2):100-8 [15098254.001]
  • [Cites] Diagn Cytopathol. 2005 Jan;32(1):21-4 [15584047.001]
  • [Cites] Acta Cytol. 2004 Nov-Dec;48(6):771-82 [15581161.001]
  • [Cites] Pathol Int. 1998 Aug;48(8):580-5 [9736404.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Feb;25(1):8-11 [12630076.001]
  • (PMID = 16467166.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1860457
  •  go-up   go-down


49. Christian CK, Kwaan MR, Betensky RA, Breen EM, Zinner MJ, Bleday R: Risk factors for perineal wound complications following abdominoperineal resection. Dis Colon Rectum; 2005 Jan;48(1):43-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with anal cancer had a higher rate of major complications than those with rectal cancer or inflammatory bowel disease.
  • Minor wound complications were more common in patients with anal cancer and inflammatory bowel disease than those with rectal cancer.
  • When the subset of patients with rectal cancer was considered, higher rates of major wounds were associated with increased body mass index, diabetes, and stage.
  • Patients with anal cancer and inflammatory bowel disease were at higher risk for perineal wound complications than those with rectal cancer.
  • Preoperative radiation and primary closure were not associated with increased complications following abdominoperineal resection for rectal cancer.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Inflammatory Bowel Diseases / complications. Perineum / injuries. Perineum / surgery. Postoperative Complications

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690656.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Johann DJ Jr, Wei BR, Prieto DA, Chan KC, Ye X, Valera VA, Simpson RM, Rudnick PA, Xiao Z, Issaq HJ, Linehan WM, Stein SE, Veenstra TD, Blonder J: Combined blood/tissue analysis for cancer biomarker discovery: application to renal cell carcinoma. Anal Chem; 2010 Mar 01;82(5):1584-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined blood/tissue analysis for cancer biomarker discovery: application to renal cell carcinoma.
  • A method that relies on subtractive tissue-directed shot-gun proteomics to identify tumor proteins in the blood of a patient newly diagnosed with cancer is described.
  • To avoid analytical and statistical biases caused by physiologic variability of protein expression in the human population, this method was applied on clinical specimens obtained from a single patient diagnosed with nonmetastatic renal cell carcinoma (RCC).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Renal Cell / blood. Kidney Neoplasms / blood

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Expert Rev Mol Diagn. 2007 Sep;7(5):473-5 [17892354.001]
  • [Cites] Nat Biotechnol. 2006 Aug;24(8):971-83 [16900146.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6958-63 [12777628.001]
  • [Cites] Histopathology. 2005 Apr;46(4):422-30 [15810954.001]
  • [Cites] J Proteome Res. 2009 May;8(5):2310-8 [19284784.001]
  • [Cites] Ann Oncol. 2009 Aug;20(8):1319-29 [19535820.001]
  • [Cites] Oncogene. 2001 Nov 22;20(53):7734-43 [11753651.001]
  • [Cites] J Urol. 2008 Jun;179(6):2096-102 [18423738.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5433-8 [17694084.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):571-9 [18385731.001]
  • [Cites] Science. 2003 Sep 5;301(5638):1380-2 [12958361.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2052-7 [15671165.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19092-9 [16684779.001]
  • [Cites] Mol Cell Proteomics. 2005 Oct;4(10):1441-4 [16020426.001]
  • [Cites] Proteomics. 2004 Jan;4(1):31-45 [14730670.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3234-7 [8764114.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] JAMA. 2001 Nov 14;286(18):2211-4 [11710876.001]
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):345-8 [10955860.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):612-20 [15701848.001]
  • [Cites] J Clin Invest. 2005 Nov;115(11):2992-3006 [16224539.001]
  • [Cites] Urol Int. 2003;70(1):55-8 [12566817.001]
  • (PMID = 20121140.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / BC / Z01 BC011023-01; United States / NCI NIH HHS / BC / Z01 BC011089-01; United States / NCI NIH HHS / BC / Z01 BC011028-01; United States / NCI NIH HHS / BC / Z01 BC011038-01; United States / NCI NIH HHS / CO / N01 CO012400; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Letter; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS175878; NLM/ PMC3251958
  •  go-up   go-down


51. Cho BC, Ahn JB, Seong J, Roh JK, Kim JH, Chung HC, Sohn JH, Kim NK: Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. BMC Cancer; 2008;8:8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients.
  • BACKGROUND: The objectives of this study were to evaluate long-term results of concurrent chemoradiotherapy (CRT) with 5-fluorouracil and cisplatin and the potential benefit of consolidation chemotherapy in patients with anal squamous cell carcinoma (ASCC).
  • CONCLUSION: our study shows that CRT with 5-FU and cisplatin, with or without consolidation chemotherapy, was well tolerated and proved highly encouraging in terms of long-term survival and the preservation of anal function in ASCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Fluorouracil / therapeutic use

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):850-6 [2724350.001]
  • [Cites] Dis Colon Rectum. 1987 Jul;30(7):495-502 [3109860.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1153-60 [2599903.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Ann Surg. 1992 Feb;215(2):150-6 [1546901.001]
  • [Cites] Dis Colon Rectum. 1992 Jun;35(6):574-7; discussion 577-8 [1587176.001]
  • [Cites] Radiother Oncol. 1993 Jun;27(3):209-15 [8210457.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):745-9 [8690640.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3121-5 [8955657.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):575-81 [9261527.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):1099-105 [9392550.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):249-56 [9572617.001]
  • [Cites] Int J Clin Oncol. 2004 Dec;9 Suppl 3:1-82 [15818867.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2650-7 [16284984.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S123-8 [16399449.001]
  • [Cites] Oncologist. 2007 Apr;12(4):451-64 [17470688.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3229-34 [18490648.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1195-202 [12599225.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2460-5 [12829663.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2933-9 [12885812.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2057-61 [14647138.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727-33 [526911.001]
  • [Cites] J Clin Gastroenterol. 1984 Jun;6(3):257-9 [6539351.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2062-8 [6435851.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] Cancer Res. 1986 Aug;46(8):3876-85 [3731062.001]
  • [Cites] Am J Med. 1989 Aug;87(2):221-4 [2527006.001]
  • (PMID = 18194582.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2245963
  •  go-up   go-down


52. Helpap B, Egevad L: [Clinical insignificance of prostate cancer: are there morphological findings?]. Urologe A; 2009 Feb;48(2):170-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical insignificance of prostate cancer: are there morphological findings?].
  • [Transliterated title] Zur klinischen Insignifikanz des Prostatakarzinoms: Gibt es morphologische Hinweise?
  • STUDY DESIGN: More than 1,000 consecutive core needle biopsy specimens of prostate carcinoma taken during 1 year (2007) were graded according to the modified Gleason scoring system.
  • Cancers with tumor infiltration of <1 mm in one of up to 12 cores and PSA <10 ng/ml mainly had low Gleason scores (6 and 7a), but only 5% of the carcinomas in the studied specimens corresponded to such a parameter.
  • [MeSH-major] Biopsy, Needle / methods. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / diagnosis


53. Claas C, Wahl J, Orlicky DJ, Karaduman H, Schnölzer M, Kempf T, Zöller M: The tetraspanin D6.1A and its molecular partners on rat carcinoma cells. Biochem J; 2005 Jul 1;389(Pt 1):99-110
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tetraspanin D6.1A and its molecular partners on rat carcinoma cells.
  • In this paper, we summarize our studies performed on the tetraspanin D6.1A/CO-029/TM4SF3 expressed by rat carcinoma cells.
  • [MeSH-minor] Animals. Antigens, CD / metabolism. Antigens, CD81. Antigens, CD9. Cell Line, Tumor. Detergents / pharmacology. Multiprotein Complexes / chemistry. Multiprotein Complexes / metabolism. Pancreatic Neoplasms / metabolism. Protein Binding / drug effects. Rats. Solubility / drug effects. Tetraspanins. Urinary Bladder Neoplasms / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2003 Dec 8;163(5):1167-77 [14662754.001]
  • [Cites] J Lipid Res. 1998 Jun;39(6):1152-61 [9643346.001]
  • [Cites] J Mol Med (Berl). 1999 Oct;77(10):699-712 [10606205.001]
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):591-602 [10662783.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5370-8 [10681511.001]
  • [Cites] FEBS Lett. 2000 Mar 3;469(1):52-6 [10708755.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9230-8 [10734060.001]
  • [Cites] Eur J Immunol. 2000 Mar;30(3):900-7 [10741407.001]
  • [Cites] J Cell Biol. 2000 May 15;149(4):969-82 [10811835.001]
  • [Cites] Nat Cell Biol. 2000 Sep;2(9):582-92 [10980698.001]
  • [Cites] Biochem J. 2000 Nov 1;351 Pt 3:629-37 [11042117.001]
  • [Cites] J Biol Chem. 2001 Apr 27;276(17):14329-37 [11278880.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):4853-62 [11087758.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):4940-7 [11087729.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):7974-84 [11113129.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9 [11413487.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):25005-13 [11325968.001]
  • [Cites] Cell Mol Life Sci. 2001 Aug;58(9):1189-205 [11577978.001]
  • [Cites] Mol Biol Cell. 1998 Oct;9(10):2751-65 [9763442.001]
  • [Cites] Biochem J. 1999 May 15;340 ( Pt 1):103-11 [10229664.001]
  • [Cites] J Immunol. 2001 Nov 1;167(9):5115-21 [11673522.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):41165-74 [11479292.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40545-54 [11504738.001]
  • [Cites] J Hepatol. 2001 Nov;35(5):637-42 [11690710.001]
  • [Cites] J Biochem. 2002 Jan;131(1):39-44 [11754733.001]
  • [Cites] Mol Biol Cell. 2002 Mar;13(3):767-81 [11907260.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):34349-58 [12068006.001]
  • [Cites] Int J Oncol. 2003 Mar;22(3):663-70 [12579322.001]
  • [Cites] Mol Biol Cell. 2003 Feb;14(2):611-24 [12589058.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Apr 25;304(1):107-12 [12705892.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5795-800 [12721375.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2665-74 [12750295.001]
  • [Cites] Cell. 2003 Aug 8;114(3):299-310 [12914695.001]
  • [Cites] Eur J Immunol. 2003 Sep;33(9):2479-89 [12938224.001]
  • [Cites] J Cell Sci. 2003 Nov 1;116(Pt 21):4373-90 [13130099.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Nov;18(11):1309-14 [14535989.001]
  • [Cites] J Cell Biol. 2003 Oct 13;163(1):165-76 [14557253.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:397-422 [14570575.001]
  • [Cites] Exp Cell Res. 2004 Jul 15;297(2):329-47 [15212938.001]
  • [Cites] Br J Cancer. 1978 Jan;37(1):61-6 [619957.001]
  • [Cites] Anal Biochem. 1984 Apr;138(1):141-3 [6731838.001]
  • [Cites] Cancer Res. 1989 Mar 1;49(5):1294-9 [2917359.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(17):6833-7 [2395876.001]
  • [Cites] J Cell Biol. 1991 Jan;112(1):159-68 [1986003.001]
  • [Cites] Nature. 1992 Mar 26;356(6367):344-6 [1549178.001]
  • [Cites] Semin Thromb Hemost. 1992;18(4):353-72 [1470924.001]
  • [Cites] Int J Cancer. 1993 Feb 20;53(4):651-6 [8436439.001]
  • [Cites] J Cell Biol. 1994 Apr;125(2):437-46 [8163559.001]
  • [Cites] J Invest Dermatol. 1994 Jun;102(6):987-91 [8006466.001]
  • [Cites] Genes Dev. 1994 Jun 1;8(11):1311-23 [7926732.001]
  • [Cites] Neuron. 1995 Aug;15(2):333-43 [7544141.001]
  • [Cites] Biochim Biophys Acta. 1996 Jun 7;1287(2-3):67-71 [8672529.001]
  • [Cites] Cell Growth Differ. 1996 May;7(5):663-78 [8732676.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1996 Apr;54(4):247-59 [8804121.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1996 Oct;55(4):261-8 [8951995.001]
  • [Cites] J Biol Chem. 1997 May 16;272(20):13236-41 [9148941.001]
  • [Cites] J Cell Biol. 1998 Apr 6;141(1):267-80 [9531564.001]
  • [Cites] Mol Biol Cell. 2004 May;15(5):2375-87 [15004227.001]
  • (PMID = 15725074.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD81; 0 / Antigens, CD9; 0 / Cd81 protein, rat; 0 / Detergents; 0 / Membrane Glycoproteins; 0 / Multiprotein Complexes; 0 / Neoplasm Proteins; 0 / Ptgfrn protein, rat; 0 / Tetraspanins; 0 / Tspan8 protein, rat
  • [Other-IDs] NLM/ PMC1184542
  •  go-up   go-down


54. Jelski W, Mroczko B, Szmitkowski M: The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients. Dig Dis Sci; 2010 Oct;55(10):2953-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients.
  • BACKGROUND: The activity of total alcohol dehydrogenase (ADH) and class I isoenzymes is significantly higher in colorectal cancer tissue than in healthy mucosa.
  • The activity of these enzymes in cancer cells is probably reflected in the sera and could thus be helpful for diagnosing colorectal cancer.
  • AIM: The aim of this study was to investigate a potential role of ADH and aldehyde dehydrogenase (ALDH) as tumor markers for colorectal cancer.
  • METHODS: Serum samples were taken from 182 patients with colorectal cancer before treatment and from 160 control subjects.
  • RESULTS: There was significant increase in the activity of ADH I isoenzyme and ADH total in the sera of colorectal cancer patients compared to the control.
  • The sensitivity and specificity of ADH I increased with the stage of the carcinoma.
  • CONCLUSION: The results suggest a potential role for ADH I as marker for colorectal cancer.
  • [MeSH-major] Alcohol Dehydrogenase / blood. Aldehyde Dehydrogenase / blood. Biomarkers / blood. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / metabolism. Isoenzymes / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 1989 Oct 23;257(1):105-9 [2806555.001]
  • [Cites] Clin Chem. 1993 Nov;39(11 Pt 1):2298-304 [8222224.001]
  • [Cites] Clin Exp Med. 2006 Jun;6(2):89-93 [16820997.001]
  • [Cites] Anal Biochem. 1989 Apr;178(1):57-62 [2729580.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):977-81 [15309886.001]
  • [Cites] Clin Exp Med. 2007 Dec;7(4):154-7 [18188528.001]
  • [Cites] Anal Biochem. 1979 Oct 15;99(1):65-71 [231394.001]
  • [Cites] Dig Dis Sci. 2005 Jun;50(6):1019-24 [15986847.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Aug;16(4):775-810 [12418049.001]
  • [Cites] Digestion. 1996;57(2):105-8 [8785998.001]
  • [Cites] Clin Chem Lab Med. 2008;46(10):1423-8 [18844497.001]
  • [Cites] Clin Chim Acta. 2006 Sep;371(1-2):143-7 [16603145.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):208-12 [17368603.001]
  • [Cites] Alcohol Clin Exp Res. 1996 May;20(3):551-5 [8727253.001]
  • [Cites] Alcohol Clin Exp Res. 1996 Dec;20(9):1569-76 [8986205.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):33-8 [16520929.001]
  • [Cites] Clin Chem Lab Med. 2003 May;41(5):646-51 [12812262.001]
  • [Cites] BMJ. 2000 Feb 12;320(7232):424-7 [10669448.001]
  • (PMID = 20069455.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Isoenzymes; EC 1.1.1.1 / Alcohol Dehydrogenase; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down


55. Schmidt B, Liebenberg V, Dietrich D, Schlegel T, Kneip C, Seegebarth A, Flemming N, Seemann S, Distler J, Lewin J, Tetzner R, Weickmann S, Wille U, Liloglou T, Raji O, Walshaw M, Fleischhacker M, Witt C, Field JK: SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer; 2010;10:600
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates.
  • BACKGROUND: This study aimed to show that SHOX2 DNA methylation is a tumor marker in patients with suspected lung cancer by using bronchial fluid aspirated during bronchoscopy.
  • Such a biomarker would be clinically valuable, especially when, following the first bronchoscopy, a final diagnosis cannot be established by histology or cytology.
  • CONCLUSIONS: Hypermethylation of SHOX2 in bronchial aspirates appears to be a clinically useful tumor marker for identifying subjects with lung carcinoma, especially if histological and cytological findings after bronchoscopy are ambiguous.
  • [MeSH-minor] Adult. Aged. Bronchoscopy / methods. Carcinoma / metabolism. Case-Control Studies. DNA Methylation. False Positive Reactions. Female. Humans. Male. Middle Aged. Nucleic Acid Hybridization. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1624-8 [11245475.001]
  • [Cites] Methods Mol Biol. 2010;576:155-70 [19882262.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Chest. 2002 May;121(5):1521-6 [12006438.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):777-85 [12360280.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3741-6 [12473584.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):129S-136S [12527572.001]
  • [Cites] Anal Cell Pathol. 2003;25(2):83-8 [12632017.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] Oncogene. 2003 Aug 21;22(35):5525-36 [12934113.001]
  • [Cites] Nucleic Acids Res. 2004;32(1):e10 [14722226.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2284-8 [15073103.001]
  • [Cites] Chest. 2004 Sep;126(3):666-8 [15364737.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2406-11 [9482898.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):41-9 [10328763.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 2:S21-7 [15552778.001]
  • [Cites] Nat Rev Genet. 2005 Aug;6(8):597-610 [16136652.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1633-45 [16273220.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7728-34 [16278393.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):451-69 [16513615.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10911-8 [17108128.001]
  • [Cites] Genes Dev. 2006 Dec 1;20(23):3215-31 [17158741.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):181-232 [17137717.001]
  • [Cites] Dis Markers. 2007;23(1-2):73-87 [17325427.001]
  • [Cites] Oncogene. 2007 Mar 1;26(10):1507-16 [16936776.001]
  • [Cites] Curr Opin Pulm Med. 2007 Jul;13(4):249-55 [17534168.001]
  • [Cites] Dev Biol. 2007 Jun 15;306(2):549-59 [17481601.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1539-50 [17499000.001]
  • [Cites] J Cell Sci. 2007 Sep 15;120(Pt 18):3163-72 [17878233.001]
  • [Cites] J Thorac Oncol. 2007 Nov;2(11):1044-51 [17975498.001]
  • [Cites] J Pathol. 2007 Dec;213(4):412-9 [17973238.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] BMC Pulm Med. 2008;8:2 [18221551.001]
  • [Cites] Mol Cancer. 2008;7:62 [18616821.001]
  • [Cites] Mol Cancer. 2008;7:81 [18947422.001]
  • [Cites] Clin Sci (Lond). 2009 Jan;116(1):27-35 [19037882.001]
  • [Cites] Adv Cancer Res. 2008;101:93-126 [19055944.001]
  • [Cites] Int J Cancer. 2009 Jan 1;124(1):81-7 [18823011.001]
  • [Cites] Biotechniques. 2009 Sep;47(3):737-44 [19852759.001]
  • [Cites] Thorax. 2002 Jan;57(1):11-4 [11809983.001]
  • (PMID = 21047392.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / SHOX2 protein, human
  • [Other-IDs] NLM/ PMC2988753
  •  go-up   go-down


56. Fox PA, Seet JE, Stebbing J, Francis N, Barton SE, Strauss S, Allen-Mersh TG, Gazzard BG, Bower M: The value of anal cytology and human papillomavirus typing in the detection of anal intraepithelial neoplasia: a review of cases from an anoscopy clinic. Sex Transm Infect; 2005 Apr;81(2):142-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of anal cytology and human papillomavirus typing in the detection of anal intraepithelial neoplasia: a review of cases from an anoscopy clinic.
  • BACKGROUND: Previous studies have reached differing conclusions about the utility of anal cytology as a screening tool for anal intraepithelial neoplasia (AIN).
  • Comparison was made between results of anal cytology using the sampling method of Palefsky, and histological findings of biopsies taken from abnormal areas seen on high resolution anoscopic examination of the anal canal.
  • At screening of 34 asymptomatic men, 83% had anal cytological dysplasia and 78% had AIN.
  • CONCLUSION: Anal cytology by the Palefsky method is simple to undertake, has a sensitivity and specificity comparable with cervical cytology, and can therefore be used as the basis of a pilot screening project in centres with large cohorts of HIV positive homosexual men who have a high risk of developing anal carcinoma.
  • [MeSH-major] Anus Neoplasms / pathology. Bisexuality. Carcinoma in Situ / pathology. Homosexuality, Male. Papillomavirus Infections / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Gay, Lesbian, Bisexual, and Transgender Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] Dis Colon Rectum. 1999 Oct;42(10):1342-4 [10528776.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] Sex Transm Infect. 2002 Apr;78(2):135-8 [12081177.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] JAMA. 1982 Apr 9;247(14):1988-90 [7062503.001]
  • [Cites] J Clin Pathol. 1986 Sep;39(9):933-44 [3760239.001]
  • [Cites] AIDS. 1993 Jan;7(1):43-9 [8382927.001]
  • [Cites] Genitourin Med. 1994 Feb;70(1):22-5 [8300094.001]
  • [Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):919-28 [9269808.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S42-8 [10430218.001]
  • [Cites] Sex Transm Infect. 1999 Jun;75(3):172-7 [10448395.001]
  • [Cites] J Virol Methods. 2000 Sep;89(1-2):29-37 [10996637.001]
  • (PMID = 15800092.001).
  • [ISSN] 1368-4973
  • [Journal-full-title] Sexually transmitted infections
  • [ISO-abbreviation] Sex Transm Infect
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1764665
  •  go-up   go-down


57. Johnson NM, Qian G, Xu L, Tietze D, Marroquin-Cardona A, Robinson A, Rodriguez M, Kaufman L, Cunningham K, Wittmer J, Guerra F, Donnelly KC, Williams JH, Wang JS, Phillips TD: Aflatoxin and PAH exposure biomarkers in a U.S. population with a high incidence of hepatocellular carcinoma. Sci Total Environ; 2010 Nov 1;408(23):6027-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aflatoxin and PAH exposure biomarkers in a U.S. population with a high incidence of hepatocellular carcinoma.
  • The incidence of hepatocellular carcinoma (HCC) is significantly elevated in a Hispanic community in Bexar County, Texas.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AFLATOXIN B1 .
  • Hazardous Substances Data Bank. L-Lysine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • [Cites] Nutr Cancer. 1999;35(1):27-33 [10624703.001]
  • [Cites] Public Health Rep. 2009 Jan-Feb;124(1):120-6 [19413034.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2002;82:1-556 [12687954.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7 Suppl):2114s-2118s [1311989.001]
  • [Cites] Lancet. 1992 Apr 18;339(8799):943-6 [1348796.001]
  • [Cites] Ann Occup Hyg. 1992 Dec;36(6):681-8 [1471819.001]
  • [Cites] J Anim Sci. 1992 Dec;70(12):3941-9 [1474031.001]
  • [Cites] Sci Total Environ. 1995 Feb 24;163(1-3):164-8 [7716494.001]
  • [Cites] Sci Total Environ. 1995 Feb 24;163(1-3):169-77 [7716495.001]
  • [Cites] Sci Total Environ. 1995 Feb 24;163(1-3):191-4 [7716498.001]
  • [Cites] Food Addit Contam. 1995 May-Jun;12(3):383-6 [7664932.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Apr;5(4):253-61 [8722216.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):523-9 [9232340.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Hepatology. 1999 Aug;30(2):379-83 [10421643.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5):1372-80 [15521006.001]
  • [Cites] Am J Clin Nutr. 2004 Nov;80(5):1106-22 [15531656.001]
  • [Cites] Int J Hyg Environ Health. 2006 Jul;209(4):345-58 [16644281.001]
  • [Cites] BMC Public Health. 2006;6:159 [16787544.001]
  • [Cites] Cancer Biomark. 2005;1(1):5-14 [17192028.001]
  • [Cites] Cancer Lett. 2007 Jul 8;252(1):104-14 [17250958.001]
  • [Cites] Am J Trop Med Hyg. 2007 Oct;77(4):747-52 [17978082.001]
  • [Cites] Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2008 May;25(5):622-34 [18478481.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1653-7 [18628416.001]
  • [Cites] Sci Total Environ. 2009 Mar 1;407(6):1886-91 [19144392.001]
  • [Cites] J Clin Gastroenterol. 2002 Sep;35(3):266-9 [12192205.001]
  • (PMID = 20870273.001).
  • [ISSN] 1879-1026
  • [Journal-full-title] The Science of the total environment
  • [ISO-abbreviation] Sci. Total Environ.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES009106; United States / NIEHS NIH HHS / ES / ES09106
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aflatoxins; 0 / Biomarkers; 0 / Environmental Pollutants; 0 / Polycyclic Hydrocarbons, Aromatic; 0 / Pyrenes; 0 / aflatoxin B1-lysine adduct; 5315-79-7 / 1-hydroxypyrene; 9N2N2Y55MH / Aflatoxin B1; AYI8EX34EU / Creatinine; K3Z4F929H6 / Lysine
  • [Other-IDs] NLM/ NIHMS236527; NLM/ PMC2993492
  •  go-up   go-down


58. Lu ZJ, Song QF, Jiang SS, Song Q, Wang W, Zhang GH, Kan B, Chen LJ, Yang JL, Luo F, Qian ZY, Wei YQ, Gou LT: Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen. BMC Cancer; 2009;9:16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen.
  • BACKGROUND: Antibody-based immunotherapy has achieved some success for cancer.
  • It is essential to identify more immunogenic antigens (especially cellular membrane markers) for tumor diagnosis and therapy.
  • METHODS: The membrane proteins of lung adenocarcinoma cell line A549 were used to immunize the BALB/c mice.
  • MTT cell proliferation assay was carried out to evaluate the inhibitory effect of McAb4E7 on A549 cells.
  • Flow cytometric assay, immunohistochemistry, western blot and proteomic technologies based on 2-DE and mass spectrometry were employed to detect and identify the corresponding antigen of McAb4E7.
  • Furthermore, immunohistochemistry showed that the antigen of McAb4E7 mainly aberrantly expressed in tumor cellular membrane in non-small cell lung cancer (NSCLC), but not in small cell lung cancer (SCLC).
  • The rate of ectopic expressed ATPB in the cellular membrane in lung adenocarcinoma, squamous carcinoma and their adjacent nontumourous lung tissues was 71.88%, 66.67% and 25.81% respectively.
  • CONCLUSION: In the present study, we identified that the ectopic ATPB in tumor cellular membrane was the non-small cell lung cancer (NSCLC) associated antigen.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / enzymology. Lung Neoplasms / enzymology. Mitochondrial Proton-Translocating ATPases / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Feb 26;355(9205):735-40 [10703815.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:59 [18983643.001]
  • [Cites] J Mol Biol. 2002 Feb 1;315(5):1063-73 [11827476.001]
  • [Cites] Leukemia. 2002 Apr;16(4):478-85 [11960325.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99 [12953083.001]
  • [Cites] Mol Cancer Res. 2003 Nov;1(13):931-9 [14638865.001]
  • [Cites] Lung Cancer. 2004 Apr;44(1):99-110 [15013588.001]
  • [Cites] Anal Chem. 2004 Apr 1;76(7):1817-23 [15053638.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3679-86 [15150128.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2184-91 [15169807.001]
  • [Cites] BMC Cancer. 2004 Aug 19;4:51 [15318946.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):273-81 [8006588.001]
  • [Cites] Annu Rev Biochem. 1997;66:717-49 [9242922.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2811-6 [10077593.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):875-82 [16424020.001]
  • [Cites] Proteomics. 2006 Jan;6(2):427-37 [16342244.001]
  • [Cites] Proteomics. 2006 Jan;6(2):438-48 [16419015.001]
  • [Cites] Curr Opin Lipidol. 2006 Jun;17(3):279-84 [16680033.001]
  • [Cites] J Bioenerg Biomembr. 2005 Dec;37(6):461-5 [16691484.001]
  • [Cites] Ann Oncol. 2006 Jun;17(6):1007-13 [16533873.001]
  • [Cites] Ann Med. 2006;38(6):429-38 [17008306.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4716-24 [17510399.001]
  • [Cites] Cancer Biother Radiopharm. 2007 Oct;22(5):704-12 [17979573.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Rev Recent Clin Trials. 2008 Sep;3(3):217-27 [18782080.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6656-61 [11381144.001]
  • (PMID = 19144153.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 3.6.3.- / Mitochondrial Proton-Translocating ATPases; EC 3.6.3.14 / ATP5B protein, human
  • [Other-IDs] NLM/ PMC2654462
  •  go-up   go-down


59. Irons R, Tsuji PA, Carlson BA, Ouyang P, Yoo MH, Xu XM, Hatfield DL, Gladyshev VN, Davis CD: Deficiency in the 15-kDa selenoprotein inhibits tumorigenicity and metastasis of colon cancer cells. Cancer Prev Res (Phila); 2010 May;3(5):630-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deficiency in the 15-kDa selenoprotein inhibits tumorigenicity and metastasis of colon cancer cells.
  • Selenium has cancer-preventive activity that is mediated, in part, through selenoproteins.
  • The role of the 15-kDa selenoprotein (Sep15) in colon cancer was assessed by preparing and using mouse colon CT26 cells stably transfected with short hairpin RNA constructs targeting Sep15.
  • The highest-scored biological functions were cancer and cellular growth and proliferation.
  • Consistent with these observations, subsequent analyses revealed a G(2)-M cell cycle arrest in cells with targeted downregulation of Sep15.
  • In contrast to CT26 cells, Sep15-targeted downregulation in Lewis lung carcinoma (LLC1) cells did not affect anchorage-dependent or anchorage-independent cell growth.
  • These data suggest tissue specificity in the cancer-protective effects of Sep15 downregulation, which are mediated, at least in part, by influencing the cell cycle.

  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Oncogene. 2009 Aug 20;28(33):2959-68 [19543318.001]
  • [Cites] J Biol Chem. 2000 Nov 10;275(45):35540-7 [10945981.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2109-22 [12612082.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Science. 2003 May 30;300(5624):1439-43 [12775843.001]
  • [Cites] J Nutr. 2003 Sep;133(9):2721-7 [12949356.001]
  • [Cites] J Nutr. 2003 Sep;133(9):2907-14 [12949386.001]
  • [Cites] Oncogene. 2004 Jun 24;23(29):5032-40 [15107826.001]
  • [Cites] J Lab Clin Med. 1967 Jul;70(1):158-69 [6066618.001]
  • [Cites] Methods Enzymol. 1995;252:199-208 [7476354.001]
  • [Cites] Dis Colon Rectum. 1996 Jun;39(6):628-31 [8646947.001]
  • [Cites] JAMA. 1996 Dec 25;276(24):1957-63 [8971064.001]
  • [Cites] Anal Biochem. 1997 Nov 1;253(1):123-5 [9356150.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5542-8 [15611090.001]
  • [Cites] J Biol Chem. 2005 Dec 16;280(50):41568-75 [16230358.001]
  • [Cites] J Nutr. 2006 May;136(5):1311-7 [16614422.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13005-8 [16565519.001]
  • [Cites] IUBMB Life. 2007 Jan;59(1):1-5 [17365173.001]
  • [Cites] Oncogene. 2007 Jul 19;26(33):4825-32 [17297447.001]
  • [Cites] PLoS One. 2007;2(10):e1112 [17971875.001]
  • [Cites] Eur J Nutr. 2008 Feb;47(1):47-54 [18239845.001]
  • [Cites] Nat Protoc. 2009;4(1):44-57 [19131956.001]
  • [Cites] Eur J Biochem. 2000 Oct;267(20):6102-9 [11012661.001]
  • (PMID = 20388823.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA080946; United States / Intramural NIH HHS / / Z99 CA999999; United States / NCI NIH HHS / CA / CA080946
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Selenoproteins; 0 / Sep15 protein, mouse
  • [Other-IDs] NLM/ NIHMS184300; NLM/ PMC2865577
  •  go-up   go-down


60. Polton G: Examining the risk of anal sac gland carcinoma in cocker spaniels. J Small Anim Pract; 2006 Sep;47(9):557
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Examining the risk of anal sac gland carcinoma in cocker spaniels.
  • [MeSH-major] Anal Gland Neoplasms / genetics. Anal Sacs. Dog Diseases / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16961479.001).
  • [ISSN] 0022-4510
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  •  go-up   go-down


61. Kiran RP, Pokala N, Rottoli M, Fazio VW: Is survival reduced for patients with anal cancer requiring surgery after failure of radiation? Analysis from a population study over two decades. Am Surg; 2009 Feb;75(2):163-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is survival reduced for patients with anal cancer requiring surgery after failure of radiation? Analysis from a population study over two decades.
  • Chemoradiotherapy is the standard treatment for anal cancer.
  • From a prospective population-based database on radiation and surgical therapy, we compare outcomes for patients with anal cancer undergoing rectal resection after radiation with patients undergoing radiation alone.
  • Patients undergoing surgical resection of the rectum after initial radiation (SRT) for squamous cell carcinoma of the anus, anal canal, cloacogenic zone, and overlapping lesions of the rectum and anal canal from 1983 to 2002 were identified from the Surveillance, Epidemiology and End Results database.
  • [MeSH-major] Anus Neoplasms / mortality. Anus Neoplasms / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280811.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Mehrotra R, Gupta A, Singh M, Ibrahim R: Application of cytology and molecular biology in diagnosing premalignant or malignant oral lesions. Mol Cancer; 2006;5:11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytological study of oral cells is a non-aggressive technique that is well accepted by the patient, and is therefore an attractive option for the early diagnosis of oral cancer, including epithelial atypia and squamous cell carcinoma.
  • Lately it has re-emerged due to improved methods and it's application in oral precancer and cancer as a diagnostic and predictive method as well as for monitoring patients.

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Pathol Med. 1998 Feb;27(2):83-6 [9526735.001]
  • [Cites] J Cancer Educ. 1998 Summer;13(2):85-9 [9659626.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2005;10 Suppl 1:E15-7 [15800463.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1991 Dec;117(12):1350-5 [1845260.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1994 Jan;77(1):95-9 [8108108.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9871-5 [7937908.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):429-32 [7977967.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):405-8 [7536508.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2656-9 [7780981.001]
  • [Cites] J Natl Cancer Inst Monogr. 1995;(17):27-9 [8573448.001]
  • [Cites] Acta Cytol. 1996 Jan-Feb;40(1):81-9 [8604579.001]
  • [Cites] Acta Cytol. 1996 Jan-Feb;40(1):107-19 [8604562.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2488-92 [8653682.001]
  • [Cites] Nat Med. 1996 Jun;2(6):682-5 [8640560.001]
  • [Cites] J Am Dent Assoc. 1999 Oct;130(10):1445-57 [10570588.001]
  • [Cites] Oral Oncol. 1999 May;35(3):296-301 [10621851.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):357-62 [10690511.001]
  • [Cites] Oral Oncol. 2000 May;36(3):272-6 [10793330.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3893-8 [10919665.001]
  • [Cites] Mol Pathol. 2000 Aug;53(4):165-72 [11040937.001]
  • [Cites] Oral Oncol. 2000 Nov;36(6):525-8 [11036246.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):939-42 [11221887.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):607-12 [11297256.001]
  • [Cites] N Engl J Med. 2001 Apr 26;344(17):1270-8 [11320386.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):211-21 [11564897.001]
  • [Cites] J Mol Diagn. 2001 Nov;3(4):164-70 [11687600.001]
  • [Cites] Compend Contin Educ Dent. 2001 Feb;22(2):99-102, 104, 106; quiz 108 [11911069.001]
  • [Cites] Gen Dent. 2001 Jan-Feb;49(1):72-82 [12004680.001]
  • [Cites] J Can Dent Assoc. 2002 Nov;68(10):617-21 [12410942.001]
  • [Cites] Mund Kiefer Gesichtschir. 2002 Nov;6(6):410-4 [12447653.001]
  • [Cites] Oral Oncol. 2003 Jul;39(5):436-44 [12747967.001]
  • [Cites] Anal Cell Pathol. 2003;25(3):139-46 [12775918.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Jun;61(6):674-7 [12796875.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1943-9 [12820484.001]
  • [Cites] Anal Cell Pathol. 2003;25(4):159-66 [14501082.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Sep;96(3):252 [14515857.001]
  • [Cites] Indian J Med Sci. 2003 Sep;57(9):400-4 [14515030.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2306-9 [14556921.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Dec;96(6):654-5 [14723218.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Apr;97(4):465-70 [15088030.001]
  • [Cites] Med Oral. 2004 May-Jul;9(3):197-203 [15122120.001]
  • [Cites] J Oral Pathol Med. 2004 Aug;33(7):398-404 [15250831.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 Aug;16(5):366-70 [15341441.001]
  • [Cites] Int Dent J. 1976 Dec;26(4):398-404 [1068977.001]
  • [Cites] J R Soc Med. 1985 Dec;78(12):995-1004 [4067983.001]
  • [Cites] Am J Surg. 1988 Oct;156(4):273-5 [3177749.001]
  • [Cites] J R Soc Med. 1988 Sep;81(9):509-13 [3184106.001]
  • [Cites] J Am Dent Assoc. 1990 May;120(5):495-9 [2335670.001]
  • [Cites] Anal Quant Cytol Histol. 1991 Feb;13(1):11-5 [2025369.001]
  • [Cites] Semin Cancer Biol. 1990 Jun;1(3):165-79 [1715788.001]
  • [Cites] Cancer. 1991 Oct 1;68(7):1611-5 [1893361.001]
  • [Cites] Acta Cytol. 1992 Sep-Oct;36(5):706-10 [1523928.001]
  • [Cites] J Oral Pathol Med. 1993 Feb;22(2):82-6 [7680377.001]
  • [Cites] Cytopathology. 1993;4(1):27-35 [8453015.001]
  • [Cites] J Clin Pathol. 1993 Apr;46(4):352-6 [7684404.001]
  • [Cites] Acta Cytol. 1996 May-Jun;40(3):496-500 [8669185.001]
  • [Cites] Br J Cancer. 1997;75(3):436-40 [9020493.001]
  • [Cites] J Oral Pathol Med. 1997 May;26(5):201-5 [9178170.001]
  • [Cites] Acta Cytol. 1998 Jan-Feb;42(1):171-7 [9479336.001]
  • [Cites] Acta Cytol. 1998 Jan-Feb;42(1):189-97 [9479339.001]
  • [Cites] Cancer. 2005 Jun 25;105(3):171-7 [15822131.001]
  • [Cites] Indian J Pathol Microbiol. 2004 Oct;47(4):497-502 [16295375.001]
  • [RetractionIn] Mol Cancer. 2012;11:57 [22905981.001]
  • (PMID = 16556320.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Retracted Publication; Review
  • [Publication-country] England
  • [Number-of-references] 68
  • [Other-IDs] NLM/ PMC1448188
  •  go-up   go-down


63. Yang SP, Lee HJ, Su Y: Molecular cloning and structural characterization of the functional human thymosin beta4 gene. Mol Cell Biochem; 2005 Apr;272(1-2):97-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of the chloramphenicol acetyltransferase (CAT) reporter constructs directed by various parts of the 5'-flanking region of this gene was evaluated by transient transfection assays using human colorectal carcinoma SW480 cells as hosts.
  • Taken together, our data provide crucial information for further dissection of the molecular mechanism(s) underlying aberrant expression of the Tbeta4 gene during malignant progression of human cancers.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):50137-42 [12393863.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):532-5 [10952316.001]
  • [Cites] Oncogene. 2002 Dec 5;21(55):8477-85 [12466967.001]
  • [Cites] Mol Cell Biol. 1987 Sep;7(9):3156-67 [3670309.001]
  • [Cites] J Virol Methods. 1997 May;65(2):153-8 [9186938.001]
  • [Cites] Genomics. 1991 Jan;9(1):174-80 [2004759.001]
  • [Cites] Mol Endocrinol. 1991 Nov;5(11):1661-8 [1779969.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):869-82 [11891186.001]
  • [Cites] J Heart Valve Dis. 2002 Sep;11(5):726-35 [12358412.001]
  • [Cites] J Biol Chem. 1991 Mar 5;266(7):4029-32 [1999398.001]
  • [Cites] Oncogene. 2004 Aug 26;23 (39):6666-71 [15235586.001]
  • [Cites] Science. 1997 Oct 24;278(5338):675-80 [9381176.001]
  • [Cites] Cell Motil Cytoskeleton. 1997;38(2):187-200 [9331222.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Mar;33(3):205-20 [11311852.001]
  • [Cites] Int J Oncol. 2002 Sep;21(3):499-507 [12168092.001]
  • [Cites] Genes Dev. 1991 Nov;5(11):1935-45 [1657708.001]
  • [Cites] J Endocrinol. 1988 Jul;118(1):155-9 [3411280.001]
  • [Cites] Blood. 1990 Sep 1;76(5):977-84 [2393720.001]
  • [Cites] Proc Natl Acad Sci U S A. 1966 Sep;56(3):1010-7 [5230175.001]
  • [Cites] Oncogene. 2003 Feb 13;22(6):919-23 [12584571.001]
  • [Cites] Biorheology. 2003;40(1-3):111-7 [12454394.001]
  • [Cites] Int J Cancer. 1991 Jul 9;48(5):672-7 [2071228.001]
  • [Cites] J Cell Sci. 1995 Dec;108 ( Pt 12):3685-94 [8719875.001]
  • [Cites] Oncogene. 2003 May 22;22(21):3297-306 [12761500.001]
  • [Cites] J Natl Cancer Inst. 2003 Nov 19;95(22):1646-7 [14625249.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Aug 16;296(2):401-5 [12163032.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):799-804 [10487837.001]
  • [Cites] Proc Natl Acad Sci U S A. 1972 Jul;69(7):1800-3 [4505657.001]
  • [Cites] Mol Cell Biochem. 2000 Jan;203(1-2):163-7 [10724345.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Biol Chem. 1991 Aug 5;266(22):14256-61 [1650352.001]
  • [Cites] Annu Rev Biochem. 1981;50:349-83 [6791577.001]
  • [Cites] Genomics. 1996 Mar 15;32(3):388-94 [8838802.001]
  • (PMID = 16010977.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AJ295158
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Codon, Initiator; 549LM7U24W / thymosin beta(4); 61512-21-8 / Thymosin
  •  go-up   go-down


64. Mannello F, Tonti GA, Canestrari F: Nutrients and nipple aspirate fluid composition: the breast microenvironment regulates protein expression and cancer aetiology. Genes Nutr; 2008 Jul;3(2):77-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutrients and nipple aspirate fluid composition: the breast microenvironment regulates protein expression and cancer aetiology.
  • The aetiology of breast cancer is complex and multifactorial, and may include diet and xenobiotic compounds.
  • A wide variation in biomolecular and hormonal composition of NAFs collected from healthy and breast cancer patient may be due to genetic and nutritional factors; however, micro- and macro-nutrients may influence the secretory status of these women, thus NAF composition and risk of breast carcinoma.
  • The aim of this overview is to highlight the detrimental/beneficial role that diet-related compounds in nipple aspirate fluid can have in breast cancer risk.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1975 Sep;46(3):302-7 [1172220.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7634-9 [15492293.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1485-94 [15342450.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):989-96 [15184255.001]
  • [Cites] Horm Metab Res. 2004 May;36(5):336-40 [15156414.001]
  • [Cites] J Nutr. 2004 May;134(5):1134-8 [15113959.001]
  • [Cites] Cancer Causes Control. 2004 Apr;15(3):295-303 [15090724.001]
  • [Cites] Curr Opin Lipidol. 2004 Apr;15(2):101-8 [15017352.001]
  • [Cites] AACN Clin Issues. 2004 Jan-Mar;15(1):119-35 [14767370.001]
  • [Cites] Carcinogenesis. 2004 Feb;25(2):189-95 [14578164.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):122-7 [14710218.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8536-41 [14679022.001]
  • [Cites] Curr Pharm Des. 2003;9(12):1023-31 [12678860.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1592-6 [12496049.001]
  • [Cites] Adv Exp Med Biol. 2001;501:143-52 [11787676.001]
  • [Cites] Am J Epidemiol. 2001 Jun 15;153(12):1142-7 [11415946.001]
  • [Cites] Nurs Res. 2001 May-Jun;50(3):172-7 [11393639.001]
  • [Cites] J Clin Lab Anal. 2000;14(6):330-5 [11138618.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):4017-24 [10566643.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1386-92 [18316559.001]
  • [Cites] Cell Oncol. 2008;30(1):51-61 [18219110.001]
  • [Cites] Eur J Cancer Prev. 2008 Feb;17(1):67-70 [18090913.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1393-9 [17627004.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):125-7 [16850243.001]
  • [Cites] Cancer Res. 1987 Oct 15;47(20):5483-7 [3652048.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jul;104(1):57-66 [17004109.001]
  • [Cites] Nutr Cancer. 2006;56(2):225-31 [17474869.001]
  • [Cites] Nutr Cancer. 2006;56(2):216-24 [17474868.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1971-6 [17266038.001]
  • [Cites] Cancer Detect Prev. 2006;30(4):322-8 [16963197.001]
  • [Cites] Breast Cancer Res Treat. 2006 May;97(1):33-9 [16317581.001]
  • [Cites] J Natl Compr Canc Netw. 2006 May;4(5):480-508 [16687096.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1209-16 [16505441.001]
  • [Cites] Am J Epidemiol. 2005 Nov 15;162(10):943-52 [16192345.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Nov;5(6):873-81 [16255629.001]
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1389-94 [15802301.001]
  • [Cites] Breast J. 2005 Mar-Apr;11(2):92-9 [15730453.001]
  • [Cites] Am J Epidemiol. 2005 Jan 15;161(2):153-60 [15632265.001]
  • [Cites] Nutr Rev. 2004 Nov;62(11):427-38 [15622715.001]
  • [Cites] Nutrition. 1999 Jun;15(6):523-6 [10378216.001]
  • [Cites] Cancer Causes Control. 1998 Jan;9(1):19-27 [9486460.001]
  • [Cites] Pharmacol Ther. 1997 Sep;75(3):185-97 [9504139.001]
  • [Cites] Breast Cancer Res Treat. 1990 Jan;15(1):39-51 [2183892.001]
  • [Cites] J Surg Oncol. 1980;15(1):59-66 [6775160.001]
  • [Cites] Cancer Res. 1981 Jun;41(6):2563-5 [7237447.001]
  • [Cites] Cancer. 1981 Mar 15;47(6):1444-50 [7226070.001]
  • [Cites] J Reprod Med. 1979 May;22(5):267-70 [572427.001]
  • [Cites] Br J Cancer. 1997;76(4):494-501 [9275027.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):785-94 [8896889.001]
  • [Cites] J Natl Cancer Inst. 1996 Oct 2;88(19):1369-74 [8827014.001]
  • [Cites] J Natl Cancer Inst. 1994 Sep 21;86(18):1419-21 [8072037.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):33-6 [8118383.001]
  • [Cites] Epidemiol Rev. 1993;15(1):188-95 [8405203.001]
  • [Cites] Br J Cancer. 1991 Jul;64(1):187-91 [1854621.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):277-80 [1303127.001]
  • [Cites] Breast Cancer Res Treat. 1988 Jul;11(3):255-62 [3167231.001]
  • [Cites] Biomed Environ Mass Spectrom. 1987 Jul;14(7):335-8 [2959341.001]
  • [Cites] Breast Cancer Res Treat. 1989 Jan;13(1):71-8 [2706328.001]
  • [Cites] Am J Clin Pathol. 1988 Jan;89(1):117-20 [3337046.001]
  • [Cites] Breast Cancer Res Treat. 1986;8(1):7-19 [3539239.001]
  • [Cites] Cancer. 2007 Jun 15;109(12 Suppl):2712-49 [17503428.001]
  • (PMID = 18850189.001).
  • [ISSN] 1555-8932
  • [Journal-full-title] Genes & nutrition
  • [ISO-abbreviation] Genes Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2467451
  •  go-up   go-down


65. Dhir AA, Sawant S, Dikshit RP, Parikh P, Srivastava S, Badwe R, Rajadhyaksha S, Dinshaw KA: Spectrum of HIV/AIDS related cancers in India. Cancer Causes Control; 2008 Mar;19(2):147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of HIV/AIDS related cancers in India.
  • OBJECTIVE: To study the cancer pattern among HIV positive cancer cases.
  • METHOD: The study group included patients registered in the HIV Cancer clinic at the Tata Memorial Hospital (TMH), Mumbai, which is the largest tertiary referral cancer center in India.
  • We used the gender and age-specific proportions of each cancer site of the year 2002 that was recorded in the Hospital Cancer Registry to estimate an expected number of various cancer sites among HIV positive cancer patients during the period 2001-2005.
  • The observed number of site-specific cancer cases was divided by the expected number to obtain proportional incidence ratio (PIR).
  • In males, PIR was increased for anal cancer (PIR = 10.3, 95%CI 4.30-24.83), Hodgkin's disease, testicular cancer, colon cancer, and few head and neck cancer sites.
  • Among females, the PIRs for cervical cancer (PIR = 4.1, 95%CI 2.90-5.75), vaginal cancer (PIR = 7.7, 95%CI 2.48-23.85), and anal cancer (PIR = 6.5, 95%CI 0.91-45.88) were increased.
  • CONCLUSIONS: The absence of Kaposi's sarcoma and increased PIRs for certain non-AIDS defining cancers among HIV infected cancer cases indicates a different spectrum of HIV associated malignancies in this region.
  • The raised PIR for cervical cancer emphasizes the urgent need for screening programs for cervical cancer among HIV infected individuals in India.


66. Ljubojević S, Lipozencić J, Skerlev M, Zele-Starcević L, Ljubojević N, Babić D, Grubisić G, Jukić S: [Diagnostic-therapeutic guidelines for men whose partners have HPV genital infection]. Lijec Vjesn; 2009 Sep-Oct;131(9-10):269-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HPV infections are connected with different diseases such as benign warts, condylomata acuminata, malignant cervical, vulvar, vaginal, penile and anal carcinoma.
  • Peniscopy with HPV detection is a specific diagnostic method for diagnosis of subclinical HPV genital infection in asymptomatic men.
  • Early diagnosis and treatment of HPV infections in men is of potential benefit because their eradication can reduce the viral reservoir and as the result of that the incidence of CIN, carcinoma in situ and invasive cervical carcinoma can be reduced.
  • For the correct diagnosis and for choosing the adequate therapeutical technique, we suggest diagnostic-therapeutic guidelines for HPV genital infection in men.
  • [MeSH-major] Papillomavirus Infections / diagnosis. Papillomavirus Infections / therapy. Penile Diseases / diagnosis. Penile Diseases / therapy

  • MedlinePlus Health Information. consumer health - Penis Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20030291.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 41
  •  go-up   go-down


67. Meyer J, Willett C, Czito B: Current and emerging treatment strategies for anal cancer. Curr Oncol Rep; 2010 May;12(3):168-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current and emerging treatment strategies for anal cancer.
  • Concurrent radiotherapy and chemotherapy (5-fluorouracil and mitomycin-C) is established as a sphincter-preserving treatment for squamous cell carcinoma of the anal canal.
  • This review discusses the evolution of therapy for anal cancer, from early clinical trials establishing the current standard to more recent studies evaluating cisplatin, capecitabine, oxaliplatin, and cetuximab.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):114-25 [6326995.001]
  • [Cites] Dis Colon Rectum. 1977 Nov-Dec;20(8):677-8 [923397.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6555-60 [18006754.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):143-9 [19203845.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Eur J Cancer. 2009 Nov;45(16):2782-91 [19643599.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72 (1):119-26 [18472366.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):474-9 [18202423.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):701-8 [10690556.001]
  • [Cites] Oncol Rep. 2007 Oct;18(4):775-8 [17786335.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):21-8 [19897418.001]
  • [Cites] Radiother Oncol. 2008 Mar;86(3):428-34 [18006097.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Dec;65(1):197-9 [19727729.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):27-33 [23154075.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31 [10219805.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30 [19117696.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • (PMID = 20425076.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 30
  •  go-up   go-down


68. Pascual I, Alvarez-Gallego M, Herreros MD, Garcia-Olmo D, García-Fernández E: Metastasis in anal mucosa from bladder cancer. Tech Coloproctol; 2006 Oct;10(3):255
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis in anal mucosa from bladder cancer.
  • [MeSH-major] Anus Neoplasms / secondary. Carcinoma, Papillary / secondary. Urinary Bladder Neoplasms / pathology


69. Zuo ZG, Song HY, Li J, Xu C, Zhou ZH, Ni SC, Chen SQ: [Clinical application of intersphincteric resection in the anal-preserving operation for ultra-low rectal carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Dec;31(12):941-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical application of intersphincteric resection in the anal-preserving operation for ultra-low rectal carcinoma].
  • OBJECTIVE: To investigate the clinical application of intersphincter resection (ISR) combined with total mesorectal excision (TME) and colon-anal anastomosis in the treatment for ultra-low rectal carcinoma.
  • METHODS: To review and analyze retrospectively the data of 34 patients with ultra-low rectal carcinoma (without external anal sphincter involvement) who received treatment of ISR, TME and colon-anal anastomosis.
  • Reconstruction of digestive tract was done by manual colon-anal anastomosis.
  • The average distance from distal excised margin to the tumor was 2.3 (1.8 - 3.2) cm among 34 patients.
  • The pathological types were as follows: 28 cases of adenocarcinoma (11 were well differentiated, 17 moderately differentiated), 1 case of papillary carcinoma and 5 cases of villous adenoma with malignant change.
  • CONCLUSION: With strictly grasping indications, radical resection can be attained and anal sphincter preserved by ISR combined with TME and colon-anal anastomosis.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Rectal Neoplasms / surgery. Rectum / surgery
  • [MeSH-minor] Adenoma, Villous / pathology. Adenoma, Villous / surgery. Adult. Aged. Aged, 80 and over. Anastomosis, Surgical. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Surgical Wound Dehiscence / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193339.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


70. Parry NM: Anal sac gland carcinoma in a cat. Vet Pathol; 2006 Nov;43(6):1008-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac gland carcinoma in a cat.
  • A perianal mass in a 15-year-old domestic shorthair cat with a history of a firm, painful swelling in the left ventrolateral perianal region was surgically excised and submitted for light microscopic evaluation.
  • Acinar lumina sometimes contained eosinophilic proteinaceous material or cell debris.
  • These microscopic features are consistent with anal sac gland carcinoma.
  • [MeSH-major] Anal Gland Neoplasms / pathology. Anal Sacs / pathology. Carcinoma / veterinary. Cat Diseases / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17099161.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Lin GL, Qiu HZ, Xiao Y, Wu B, Meng WC: [Transanal endoscopic microsurgery for rectal intraepithelial neoplasia and early rectal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jan;11(1):39-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transanal endoscopic microsurgery for rectal intraepithelial neoplasia and early rectal carcinoma].
  • OBJECTIVE: To investigate the clinical value of transanal endoscopic microsurgery (TEM) for rectal intraepithelial neoplasia (IN) and early rectal carcinoma.
  • The pre-operative diagnosis by biopsy and endoanal ultrasonography (EUS): rectal low-grade IN in 8 cases, high-grade IN in 4 and early rectal carcinoma in 3.
  • The average distance of tumors from the anal verge was 7.2(4-15) cm.
  • The post-operative pathological diagnosis: rectal low-grade IN in 5 cases, high-grade IN in 6, early submucous invasive carcinoma (pT(1)) in 2, advanced carcinoma (pT(2)) in 2.
  • CONCLUSION: TEM is an ideal minimally invasive procedure for the treatment of rectal IN and early rectal carcinoma, with excellent exposure and accurate excision, providing a high-quality tumor specimen for pathological staging.
  • [MeSH-major] Anal Canal / surgery. Microsurgery. Rectal Neoplasms / surgery. Rectum / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18197492.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


72. Safioleas MC, Moulakakis KG, Stamatakos M, Kountouras J, Lygidakis NJ: Local recurrence following curative low anterior resection for rectal carcinoma. Hepatogastroenterology; 2005 Jan-Feb;52(61):94-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrence following curative low anterior resection for rectal carcinoma.
  • BACKGROUND/AIMS: Local recurrence is a formidable problem after potentially curative resection for rectal cancer.
  • We attempted to identify possible factors affecting the frequency of local recurrence, focusing on the clearance of the tumor and the margin of resection.
  • METHODOLOGY: The clinical cohort consisted of 66 patients suffering from rectal carcinoma.
  • RESULTS: Analysis by distance of the tumor from the anal verge revealed that 5 out of 33 patients (15.15%) from the upper rectal group and 7 out of 19 patients (36.8%) from the mid rectal group developed local recurrences (36.8% vs. 15.15% P=0.0369).
  • [MeSH-major] Carcinoma / mortality. Carcinoma / surgery. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / mortality. Rectal Neoplasms / mortality. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783003.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


73. Kreuter A, Brockmeyer NH, Altmeyer P, Wieland U, German Competence Network HIV/AIDS: Anal intraepithelial neoplasia in HIV infection. J Dtsch Dermatol Ges; 2008 Nov;6(11):925-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia in HIV infection.
  • In HIV-infected men who have sex with men (MSM), anal HPV prevalence is more than 90% and infections with multiple HPV types are common.
  • Anal intraepithelial neoplasia (AIN) is a potential precursor lesion of squamous cell carcinoma of the anus.
  • As AIN and CIN share distinct biological similar-ities, AIN screenings analogous to Pap smear programs for CIN have been recommended in high-risk populations to reduce the incidence of anal carcinoma.
  • These screenings include cytological analysis followed by high resolution anoscopy in case of anal dysplasia.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. HIV Infections / diagnosis. HIV Infections / therapy. Papillomavirus Infections / diagnosis. Papillomavirus Infections / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410393.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 46
  •  go-up   go-down


74. Han SL, Zeng QQ, Shen X, Zheng XF, Guo SC, Yan JY: The indication and surgical results of local excision following radiotherapy for low rectal cancer. Colorectal Dis; 2010 Nov;12(11):1094-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The indication and surgical results of local excision following radiotherapy for low rectal cancer.
  • AIM: Radical surgery of rectal cancer is associated with significant morbidity, and some patients with low-lying lesions must accept a permanent colostomy.
  • The objective of this study was to evaluate the outcome of local excision followed by adjuvant radiotherapy for rectal cancer for curative purposes.
  • METHOD: One hundred and seven patients with rectal carcinoma performed with local excision were analysed retrospectively.
  • RESULTS: The procedures of local excision were trans-anal resection in 83 patients, trans-sacral resection in 16, trans-sphincteric local resection in five, and trans-vaginal resection in three.
  • CONCLUSIONS: Local excision followed adjuvant radiotherapy is an alternative and feasible technique for small T1 rectal cancer in selected cases.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Colorectal Disease © 2010 The Association of Coloproctology of Great Britain and Ireland.
  • (PMID = 19863609.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Borel M, Degoul F, Communal Y, Mounetou E, Bouchon B, C-Gaudreault R, Madelmont JC, Miot-Noirault E: N-(4-iodophenyl)-N'-(2-chloroethyl)urea as a microtubule disrupter: in vitro and in vivo profiling of antitumoral a